AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaHumanitiesInformation ScienceHealth CareGeographicals
ChemoradiotherapyChemoradiotherapy, AdjuvantChemotherapy, AdjuvantCombined Modality TherapyRadiotherapy, AdjuvantAdjuvants, ImmunologicFluorouracilEsophageal NeoplasmsNeoadjuvant TherapyCisplatinAntineoplastic Combined Chemotherapy ProtocolsRectal NeoplasmsCarcinoma, Squamous CellRadiotherapy DosageTreatment OutcomeNeoplasm StagingHead and Neck NeoplasmsEsophagectomyDisease-Free SurvivalFreund's AdjuvantRadiotherapySurvival AnalysisSurvival RateAdenocarcinomaNeoplasm Recurrence, LocalDose FractionationNasopharyngeal NeoplasmsDeoxycytidineAntimetabolites, AntineoplasticPrognosisInduction ChemotherapyRetrospective StudiesKaplan-Meier EstimateAntineoplastic AgentsHypopharyngeal NeoplasmsLung NeoplasmsOrgan Sparing TreatmentsDrug Administration ScheduleCarboplatinLaryngeal NeoplasmsFollow-Up StudiesAdjuvants, PharmaceuticDeglutition DisordersRadiation InjuriesPreoperative CareRadiotherapy, ConformalCarcinoma, Non-Small-Cell LungOropharyngeal NeoplasmsPositron-Emission TomographyTaxoidsMucositisPaclitaxelDigestive System Surgical ProceduresLeucovorinLymphatic MetastasisRadiation-Sensitizing AgentsHydroxyureaOrganoplatinum CompoundsBrachytherapyEsophagogastric JunctionRemission InductionFluorodeoxyglucose F18Uterine Cervical NeoplasmsPancreatic NeoplasmsAnus NeoplasmsGastrectomyTegafurOxonic AcidRadiotherapy, Intensity-ModulatedEsophagitisOtorhinolaryngologic NeoplasmsTime FactorsLymph Node ExcisionLaryngectomyFeasibility StudiesPelvic NeoplasmsRandomized Controlled Trials as TopicPostoperative CareCarcinomaLarynxRadiation PneumonitisRadiopharmaceuticalsStomatitisLymphatic IrradiationPneumonectomyStomach NeoplasmsVoice DisordersMitomycinBreast NeoplasmsCyclophosphamideRadiotherapy, High-EnergyEtoposideLeukopeniaTreatment FailureNeoplasm MetastasisNeoplasms, Squamous CellTomography, X-Ray ComputedProspective StudiesAluminum HydroxideClinical Trials, Phase II as TopicClinical Trials as TopicSalvage TherapyProportional Hazards ModelsRadiation DosageMuscle NeoplasmsAntineoplastic Agents, AlkylatingMultivariate AnalysisCarcinoma, Small CellTransplantation, AutologousTumor Markers, BiologicalDose-Response Relationship, RadiationLymph NodesPredictive Value of TestsBone Marrow PurgingBrain NeoplasmsDoxorubicinVinblastinePharyngeal NeoplasmsVincristineRisk AssessmentDisease ProgressionDacarbazineBone Marrow TransplantationNeoplasm InvasivenessCystectomyAntibodies, Monoclonal, HumanizedImmunizationTrismusTamoxifenGlottisNose NeoplasmsMaximum Tolerated DoseIfosfamidePatient SelectionCamptothecinRecurrenceTumor BurdenMultimodal ImagingDrug-Related Side Effects and Adverse ReactionsPostoperative PeriodCarcinoma, Signet Ring CellNeoplasm, ResidualQuality of LifeDrug CombinationsClinical Trials, Phase III as TopicEpirubicinAntineoplastic Agents, HormonalImmunohistochemistryCarcinoma, AdenosquamousMethotrexatePharyngectomyProbabilityDeglutitionRadiation ToleranceVaccinesAdministration, IntranasalNeoplasms, Second PrimaryAmifostineAntibodies, MonoclonalNeck DissectionTracheal NeoplasmsUrinary Bladder NeoplasmsMice, Inbred BALB CJapanMedical OncologyEsophageal FistulaInfusions, IntravenousRisk FactorsRadiation OncologyPostoperative ComplicationsCranial IrradiationGlioblastomaArea Under CurveCohort StudiesSarcomaArthritis, ExperimentalLymphoma, Non-HodgkinNeutropeniaCarcinoma, Large CellAntibody FormationMouth NeoplasmsThoracotomyEndosonographyFatal OutcomeVaccines, SubunitUracilDose-Response Relationship, DrugDilatationMelphalanTriazinesThrombocytopeniaWhole-Body IrradiationImmunoglobulin GSmall Cell Lung CarcinomaPelvic BonesRadiotherapy Planning, Computer-AssistedPreoperative PeriodSqualeneThymidylate SynthaseVaccinationOvalbumin
Chemoradiotherapy: Treatment that combines chemotherapy with radiotherapy.Chemoradiotherapy, Adjuvant: Combined chemotherapy and radiotherapy given to augment some other form of treatment such as surgery. It is commonly used in the therapy of cancer.Chemotherapy, Adjuvant: Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Radiotherapy, Adjuvant: Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.Adjuvants, Immunologic: Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.Esophageal Neoplasms: Tumors or cancer of the ESOPHAGUS.Neoadjuvant Therapy: Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.Cisplatin: An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Rectal Neoplasms: Tumors or cancer of the RECTUM.Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)Radiotherapy Dosage: The total amount of radiation absorbed by tissues as a result of radiotherapy.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)Esophagectomy: Excision of part (partial) or all (total) of the esophagus. (Dorland, 28th ed)Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.Freund's Adjuvant: An antigen solution emulsified in mineral oil. The complete form is made up of killed, dried mycobacteria, usually M. tuberculosis, suspended in the oil phase. It is effective in stimulating cell-mediated immunity (IMMUNITY, CELLULAR) and potentiates the production of certain IMMUNOGLOBULINS in some animals. The incomplete form does not contain mycobacteria.Radiotherapy: The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Dose Fractionation: Administration of the total dose of radiation (RADIATION DOSAGE) in parts, at timed intervals.Nasopharyngeal Neoplasms: Tumors or cancer of the NASOPHARYNX.DeoxycytidineAntimetabolites, Antineoplastic: Antimetabolites that are useful in cancer chemotherapy.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Induction Chemotherapy: Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Kaplan-Meier Estimate: A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Hypopharyngeal Neoplasms: Tumors or cancer of the HYPOPHARYNX.Lung Neoplasms: Tumors or cancer of the LUNG.Organ Sparing Treatments: Techniques, procedures, and therapies carried out on diseased organs in such a way to avoid complete removal of the organ and preserve the remaining organ function.Drug Administration Schedule: Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.Carboplatin: An organoplatinum compound that possesses antineoplastic activity.Laryngeal Neoplasms: Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Adjuvants, Pharmaceutic: Agents that aid or increase the action of the principle drug (DRUG SYNERGISM) or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug (PHARMACOKINETICS) in such a way as to enhance its effects.Deglutition Disorders: Difficulty in SWALLOWING which may result from neuromuscular disorder or mechanical obstruction. Dysphagia is classified into two distinct types: oropharyngeal dysphagia due to malfunction of the PHARYNX and UPPER ESOPHAGEAL SPHINCTER; and esophageal dysphagia due to malfunction of the ESOPHAGUS.Radiation Injuries: Harmful effects of non-experimental exposure to ionizing or non-ionizing radiation in VERTEBRATES.Preoperative Care: Care given during the period prior to undergoing surgery when psychological and physical preparations are made according to the special needs of the individual patient. This period spans the time between admission to the hospital to the time the surgery begins. (From Dictionary of Health Services Management, 2d ed)Radiotherapy, Conformal: Radiotherapy where there is improved dose homogeneity within the tumor and reduced dosage to uninvolved structures. The precise shaping of dose distribution is achieved via the use of computer-controlled multileaf collimators.Carcinoma, Non-Small-Cell Lung: A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.Oropharyngeal Neoplasms: Tumors or cancer of the OROPHARYNX.Positron-Emission Tomography: An imaging technique using compounds labelled with short-lived positron-emitting radionuclides (such as carbon-11, nitrogen-13, oxygen-15 and fluorine-18) to measure cell metabolism. It has been useful in study of soft tissues such as CANCER; CARDIOVASCULAR SYSTEM; and brain. SINGLE-PHOTON EMISSION-COMPUTED TOMOGRAPHY is closely related to positron emission tomography, but uses isotopes with longer half-lives and resolution is lower.Taxoids: A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.Mucositis: An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).Paclitaxel: A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.Digestive System Surgical Procedures: Surgery performed on the digestive system or its parts.Leucovorin: The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS.Lymphatic Metastasis: Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.Radiation-Sensitizing Agents: Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells.Hydroxyurea: An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.Organoplatinum Compounds: Organic compounds which contain platinum as an integral part of the molecule.Brachytherapy: A collective term for interstitial, intracavity, and surface radiotherapy. It uses small sealed or partly-sealed sources that may be placed on or near the body surface or within a natural body cavity or implanted directly into the tissues.Esophagogastric Junction: The area covering the terminal portion of ESOPHAGUS and the beginning of STOMACH at the cardiac orifice.Remission Induction: Therapeutic act or process that initiates a response to a complete or partial remission level.Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)Uterine Cervical Neoplasms: Tumors or cancer of the UTERINE CERVIX.Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).Anus Neoplasms: Tumors or cancer of the ANAL CANAL.Gastrectomy: Excision of the whole (total gastrectomy) or part (subtotal gastrectomy, partial gastrectomy, gastric resection) of the stomach. (Dorland, 28th ed)Tegafur: Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms.Oxonic Acid: Antagonist of urate oxidase.Radiotherapy, Intensity-Modulated: CONFORMAL RADIOTHERAPY that combines several intensity-modulated beams to provide improved dose homogeneity and highly conformal dose distributions.Esophagitis: INFLAMMATION, acute or chronic, of the ESOPHAGUS caused by BACTERIA, chemicals, or TRAUMA.Otorhinolaryngologic Neoplasms: A general concept for tumors or cancer of any part of the EAR; the NOSE; the THROAT; and the PHARYNX. It is used when there is no specific heading.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Lymph Node Excision: Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966)Laryngectomy: Total or partial excision of the larynx.Feasibility Studies: Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.Pelvic Neoplasms: Tumors or cancer of the pelvic region.Randomized Controlled Trials as Topic: Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.Postoperative Care: The period of care beginning when the patient is removed from surgery and aimed at meeting the patient's psychological and physical needs directly after surgery. (From Dictionary of Health Services Management, 2d ed)Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Larynx: A tubular organ of VOICE production. It is located in the anterior neck, superior to the TRACHEA and inferior to the tongue and HYOID BONE.Radiation Pneumonitis: Inflammation of the lung due to harmful effects of ionizing or non-ionizing radiation.Radiopharmaceuticals: Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)Stomatitis: INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.Lymphatic Irradiation: External or interstitial irradiation to treat lymphomas (e.g., Hodgkin's and non-Hodgkin's lymphomas) and lymph node metastases and also some autoimmune diseases, such as rheumatoid arthritis.Pneumonectomy: The excision of lung tissue including partial or total lung lobectomy.Stomach Neoplasms: Tumors or cancer of the STOMACH.Voice Disorders: Pathological processes that affect voice production, usually involving VOCAL CORDS and the LARYNGEAL MUCOSA. Voice disorders can be caused by organic (anatomical), or functional (emotional or psychological) factors leading to DYSPHONIA; APHONIA; and defects in VOICE QUALITY, loudness, and pitch.Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.Breast Neoplasms: Tumors or cancer of the human BREAST.Cyclophosphamide: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.Radiotherapy, High-Energy: Radiotherapy using high-energy (megavolt or higher) ionizing radiation. Types of radiation include gamma rays, produced by a radioisotope within a teletherapy unit; x-rays, electrons, protons, alpha particles (helium ions) and heavy charged ions, produced by particle acceleration; and neutrons and pi-mesons (pions), produced as secondary particles following bombardment of a target with a primary particle.Etoposide: A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.LeukopeniaTreatment Failure: A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series.Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.Neoplasms, Squamous Cell: Neoplasms of the SQUAMOUS EPITHELIAL CELLS. The concept does not refer to neoplasms located in tissue composed of squamous elements.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Prospective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.Aluminum Hydroxide: A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc.Clinical Trials, Phase II as Topic: Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.Clinical Trials as Topic: Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.Salvage Therapy: A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.Proportional Hazards Models: Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.Radiation Dosage: The amount of radiation energy that is deposited in a unit mass of material, such as tissues of plants or animal. In RADIOTHERAPY, radiation dosage is expressed in gray units (Gy). In RADIOLOGIC HEALTH, the dosage is expressed by the product of absorbed dose (Gy) and quality factor (a function of linear energy transfer), and is called radiation dose equivalent in sievert units (Sv).Muscle Neoplasms: Tumors or cancer located in muscle tissue or specific muscles. They are differentiated from NEOPLASMS, MUSCLE TISSUE which are neoplasms composed of skeletal, cardiac, or smooth muscle tissue, such as MYOSARCOMA or LEIOMYOMA.Antineoplastic Agents, Alkylating: A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)Multivariate Analysis: A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.Carcinoma, Small Cell: An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)Transplantation, Autologous: Transplantation of an individual's own tissue from one site to another site.Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Dose-Response Relationship, Radiation: The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation.Lymph Nodes: They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.Predictive Value of Tests: In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.Bone Marrow Purging: Techniques for the removal of subpopulations of cells (usually residual tumor cells) from the bone marrow ex vivo before it is infused. The purging is achieved by a variety of agents including pharmacologic agents, biophysical agents (laser photoirradiation or radioisotopes) and immunologic agents. Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION.Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.Doxorubicin: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.Vinblastine: Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)Pharyngeal Neoplasms: Tumors or cancer of the PHARYNX.Vincristine: An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)Risk Assessment: The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)Disease Progression: The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.Dacarbazine: An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)Bone Marrow Transplantation: The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.Neoplasm Invasiveness: Ability of neoplasms to infiltrate and actively destroy surrounding tissue.Cystectomy: Used for excision of the urinary bladder.Antibodies, Monoclonal, Humanized: Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.Immunization: Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).Trismus: Spasmodic contraction of the masseter muscle resulting in forceful jaw closure. This may be seen with a variety of diseases, including TETANUS, as a complication of radiation therapy, trauma, or in association with neoplastic conditions.Tamoxifen: One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.Glottis: The vocal apparatus of the larynx, situated in the middle section of the larynx. Glottis consists of the VOCAL FOLDS and an opening (rima glottidis) between the folds.Nose Neoplasms: Tumors or cancer of the NOSE.Maximum Tolerated Dose: The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)Ifosfamide: Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.Patient Selection: Criteria and standards used for the determination of the appropriateness of the inclusion of patients with specific conditions in proposed treatment plans and the criteria used for the inclusion of subjects in various clinical trials and other research protocols.Camptothecin: An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.Recurrence: The return of a sign, symptom, or disease after a remission.Tumor Burden: The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.Multimodal Imaging: The use of combination of imaging techniques or platforms (e.g., MRI SCAN and PET SCAN) encompassing aspects of anatomical, functional, or molecular imaging methods.Drug-Related Side Effects and Adverse Reactions: Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.Postoperative Period: The period following a surgical operation.Carcinoma, Signet Ring Cell: A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.Neoplasm, Residual: Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)Quality of Life: A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment; the overall condition of a human life.Drug Combinations: Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.Clinical Trials, Phase III as Topic: Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.Antineoplastic Agents, Hormonal: Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Carcinoma, Adenosquamous: A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.Methotrexate: An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.Pharyngectomy: Surgical removal of a part of the pharynx. (Dorland, 28th ed)Probability: The study of chance processes or the relative frequency characterizing a chance process.Deglutition: The act of taking solids and liquids into the GASTROINTESTINAL TRACT through the mouth and throat.Radiation Tolerance: The ability of some cells or tissues to survive lethal doses of IONIZING RADIATION. Tolerance depends on the species, cell type, and physical and chemical variables, including RADIATION-PROTECTIVE AGENTS and RADIATION-SENSITIZING AGENTS.Vaccines: Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.Administration, Intranasal: Delivery of medications through the nasal mucosa.Neoplasms, Second Primary: Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Neck Dissection: Dissection in the neck to remove all disease tissues including cervical LYMPH NODES and to leave an adequate margin of normal tissue. This type of surgery is usually used in tumors or cervical metastases in the head and neck. The prototype of neck dissection is the radical neck dissection described by Crile in 1906.Tracheal NeoplasmsUrinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.Mice, Inbred BALB CJapanMedical Oncology: A subspecialty of internal medicine concerned with the study of neoplasms.Esophageal Fistula: Abnormal passage communicating with the ESOPHAGUS. The most common type is TRACHEOESOPHAGEAL FISTULA between the esophagus and the TRACHEA.Infusions, Intravenous: The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Radiation Oncology: A subspecialty of medical oncology and radiology concerned with the radiotherapy of cancer.Postoperative Complications: Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.Cranial Irradiation: The exposure of the head to roentgen rays or other forms of radioactivity for therapeutic or preventive purposes.Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.Area Under Curve: A statistical means of summarizing information from a series of measurements on one individual. It is frequently used in clinical pharmacology where the AUC from serum levels can be interpreted as the total uptake of whatever has been administered. As a plot of the concentration of a drug against time, after a single dose of medicine, producing a standard shape curve, it is a means of comparing the bioavailability of the same drug made by different companies. (From Winslade, Dictionary of Clinical Research, 1992)Cohort Studies: Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.Sarcoma: A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.Arthritis, Experimental: ARTHRITIS that is induced in experimental animals. Immunological methods and infectious agents can be used to develop experimental arthritis models. These methods include injections of stimulators of the immune response, such as an adjuvant (ADJUVANTS, IMMUNOLOGIC) or COLLAGEN.Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.Carcinoma, Large Cell: A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)Antibody Formation: The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.Mouth Neoplasms: Tumors or cancer of the MOUTH.Thoracotomy: Surgical incision into the chest wall.Endosonography: Ultrasonography of internal organs using an ultrasound transducer sometimes mounted on a fiberoptic endoscope. In endosonography the transducer converts electronic signals into acoustic pulses or continuous waves and acts also as a receiver to detect reflected pulses from within the organ. An audiovisual-electronic interface converts the detected or processed echo signals, which pass through the electronics of the instrument, into a form that the technologist can evaluate. The procedure should not be confused with ENDOSCOPY which employs a special instrument called an endoscope. The "endo-" of endosonography refers to the examination of tissue within hollow organs, with reference to the usual ultrasonography procedure which is performed externally or transcutaneously.Fatal Outcome: Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.Vaccines, Subunit: Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.UracilDose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Dilatation: The act of dilating.Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.Triazines: Heterocyclic rings containing three nitrogen atoms, commonly in 1,2,4 or 1,3,5 or 2,4,6 formats. Some are used as HERBICIDES.Thrombocytopenia: A subnormal level of BLOOD PLATELETS.Whole-Body Irradiation: Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.Immunoglobulin G: The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.Small Cell Lung Carcinoma: A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).Pelvic Bones: Bones that constitute each half of the pelvic girdle in VERTEBRATES, formed by fusion of the ILIUM; ISCHIUM; and PUBIC BONE.Radiotherapy Planning, Computer-Assisted: Computer-assisted mathematical calculations of beam angles, intensities of radiation, and duration of irradiation in radiotherapy.Preoperative Period: The period before a surgical operation.SqualeneThymidylate Synthase: An enzyme of the transferase class that catalyzes the reaction 5,10-methylenetetrahydrofolate and dUMP to dihydrofolate and dTMP in the synthesis of thymidine triphosphate. (From Dorland, 27th ed) EC 2.1.1.45.Vaccination: Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.

The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704. (1/158)

 (+info)

Long-term toxic effects of adjuvant chemotherapy in breast cancer. (2/158)

 (+info)

Elevation in exhaled nitric oxide predicts for radiation pneumonitis. (3/158)

 (+info)

Is surgery indicated in patients with stage IIIa lung cancer and mediastinal nodal involvement? (4/158)

 (+info)

Lymphoepithelial carcinoma: two case reports and a systematic review of oral and sinonasal cases. (5/158)

 (+info)

Adjuvant Therapy of Pancreatic Cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. (6/158)

Strong evidence exists for the use of adjuvant chemotherapy following surgical resection in pancreatic cancer, whereas the role of adjuvant chemoradiotherapy remains controversial. The optimal time to initiate adjuvant therapy has yet to be elucidated, but is usually started 2-10 weeks following resection. First line adjuvant chemotherapy is gemcitabine, as this drug has demonstrated the better efficacy in studies. Other chemotherapeutic agents and gemcitabine in combination with biologic agents are under investigation. Furthermore, predicting response to gemcitabine based chemotherapy and other adjuvant therapies will be invaluable in guiding the practitioner to choose the most appropriate adjuvant treatment. Once adjuvant therapy has been started, accurately quantifying response to therapy is also important. The adjuvant regimen may be appropriately modified if response is inadequate. This review is an update from the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting regarding recent developments in the adjuvant treatment of pancreatic cancer with regards to choice of adjuvant regimen, timing of adjuvant therapy, predicting response to therapy and measuring response to adjuvant therapy. We will present the findings from Abstracts #4039, #4042, #e14519, #4118, and #4024. In conclusion, multiple adjuvant therapeutic regimens are associated with incremental improvements in the management of pancreatic cancer. The timing of initiation of adjuvant therapy appears to be important in outcomes. Research is ongoing into markers that can predict response to adjuvant therapy.  (+info)

Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. (7/158)

 (+info)

Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). (8/158)

 (+info)

The updated outcomes of bladder-preserving trimodal therapy using a real-time tumor-tracking radiotherapy system for patients...  The updated outcomes of bladder-preserving trimodal therapy using a real-time tumor-tracking radiotherapy system for patients...
Bladder-preserving trimodal therapy is recognized as a promising alternative treatment for muscle-invasive bladder cancer. We report the updated outcomes of muscle-invasive bladder cancer patients that were treated using our treatment protocol, which involves radiotherapy delivered with a real-time tumor-tracking radiotherapy system.
https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/118607-the-updated-outcomes-of-bladder-preserving-trimodal-therapy-using-a-real-time-tumor-tracking-radiotherapy-system-for-patients-with-muscle-invasive-bladder-cancer.html
Human trimodal perception follows optimal statistical inference | JOV | ARVO Journals  Human trimodal perception follows optimal statistical inference | JOV | ARVO Journals
However, as previously mentioned, it is the incongruent conditions that probe the statistical inference rules that the nervous system must use in resolving potential conflicts in sensory cues. In incongruent conditions, there are often considerable deviations from the veridical response in one or more of the modalities. In other words, the information in the task-irrelevant one or two modalities affects the response distribution in the task-relevant modality. However, not all differences between two response distributions necessarily reflect meaningful interactions between modalities, as they may be due to sampling error. For example, the change in the visual response between unimodal condition [ V = 1, A = 0, T = 0] and bimodal condition [ V = 1, A = 2, T = 0] may be either statistically insignificant or could correspond to a statistically significant modulation of visual perception by sound. Therefore, to find which of the changes between two conditions correspond to a statistically ...
http://jov.arvojournals.org/article.aspx?articleid=2122305
Patients With Resectable Esophageal Adenocarcinoma Benefit From Neoadjuvant Chemoradiotherapy - Redorbit  Patients With Resectable Esophageal Adenocarcinoma Benefit From Neoadjuvant Chemoradiotherapy - Redorbit
Esophageal carcinoma (EC) is one of the major malignant diseases worldwide. Surgery alone cannot obtain satisfactory effects in patients with EC. Neoadjuvant chemoradiotherapy has been a hotspot for EC treatment research. Several related randomized controlled trials (RCTs) have been published, but opinions vary among clinicians as to the therapeutic effect of the new method. It remains uncertain whether patients with resectable EC can benefit from neoadjuvant chemoradiotherapy.. A research article to be published on December 21, 2009 in the World Journal of Gastroenterology addresses this question. The research team from China selected eleven randomized controlled trials (RCTs) including 1308 patients. The reuslts showed neoadjuvant chemoradiotherapy significantly improved the overall survival compared with surgery alone. Histological subgroup analysis indicated that esophageal squamous cell carcinoma did not benefit from neoadjuvant chemoradiotherapy.. Their meta-analysis suggest that patients ...
http://www.redorbit.com/news/health/1810120/patients_with_resectable_esophageal_adenocarcinoma_benefit_from_neoadjuvant_chemoradiotherapy/
Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma | Scientific Reports  Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma | Scientific Reports
To evaluate the benefit of adjuvant treatments, such as chemoradiotherapy (CRT) and chemotherapy (CTx), compared with no adjuvant treatment (No-AT) in resected gallbladder (GB) cancer patients, 151 patients were analyzed: 98 (64.9%) patients received adjuvant treatment with CRT (n = 59, 39.1%) or CTx (n = 39, 25.8%), and the remaining 53 (35.1%) did not (No-AT). The clinicopathological factors, patterns of failure, locoregional recurrence-free survival (LRFS), recurrence-free survival (RFS) and overall survival (OS) were compared among the three groups according to tumor stage. In patients with T2-3N0M0 stage disease, the incidences of locoregional recurrence and distant recurrence and 5-year LRFS, RFS and OS rates were not significantly different among the No-AT, CTx, and CRT groups (p | 0.05 each). In those with T2-3N1-2M0 stage disease, the incidences of locoregional recurrence (11.4%, 78.1%, and 68.4%, respectively) and distant recurrence (42.8%, 73.9% and 66.7%, respectively) in the CRT group were
https://www.nature.com/articles/s41598-019-48099-z?error=cookies_not_supported&code=17cbe871-ee5b-460a-936a-c49d50241a76
MicroRNA-330-5p as a putative modulator of neoadjuvant chemoradiotherapy sensitivity in oesophageal adenocarcinoma  MicroRNA-330-5p as a putative modulator of neoadjuvant chemoradiotherapy sensitivity in oesophageal adenocarcinoma
Oesophageal adenocarcinoma (OAC) is the sixth most common cause of cancer deaths worldwide, and the 5-year survival rate for patients diagnosed with the disease is approximately 17%. The standard of care for locally advanced disease is neoadjuvant chemotherapy or, more commonly, combined neoadjuvant chemoradiation therapy (neo-CRT) prior to surgery. Unfortunately, ~60-70% of patients will fail to respond to neo-CRT. Therefore, the identification of biomarkers indicative of patient response to treatment has significant clinical implications in the stratification of patient treatment. Furthermore, understanding the molecular mechanisms underpinning tumour response and resistance to neo-CRT will contribute towards the identification of novel therapeutic targets for enhancing OAC sensitivity to CRT. MicroRNAs (miRNA/miR) function to regulate gene and protein expression and play a causal role in cancer development and progression. MiRNAs have also been identified as modulators of key cellular ...
http://www.tara.tcd.ie/handle/2262/79636
Management of Borderline Resectable Pancreas Cancer  Management of Borderline Resectable Pancreas Cancer
In this segment, Tanios Bekaii-Saab, MD, FACP; Johanna C. Bendell, MD; Ramesh K. Ramanathan, MD; and Thomas Seufferlein, MD, review their protocols for treating borderline resectable pancreas cancer and considerations in making decisions about the appropriateness for recommending surgery after chemotherapy.
http://www.onclive.com/peer-exchange/pancreatic-viewpoints/management-of-borderline-resectable-pancreas-cancer?sp=patients
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre,...  Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre,...
Noordman, B.J.; Spaander, M.C.W.; Valkema, R.; Wijnhoven, B.P.; Berge Henegouwen, M.I. van; Shapiro, J.; Siersema, P.D.; Janssen, M.J.R.; Post, R.S. van der; Radema, S.A.; Rosman, C. ; Rütten, H.; Lanschot, J.J. van; Steyerberg, E.W. ...
https://repository.ubn.ru.nl/handle/2066/194346
Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced...  Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced...
The purpose of this study is to see how effective and safe LY2157299, in combination with chemotherapy and radiation therapy, might be in treating rectal
http://adisinsight.springer.com/trials/700268229?error=cookies_not_supported&code=3fd06787-4396-430e-a8a7-013f42b3acd7
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer - No Study Results Posted -...  Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer - No Study Results Posted -...
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...
https://clinicaltrials.gov/ct2/show/results/NCT01836432
NLNK) - NewLink Genetics Announces Phase 3 Clinical Trial of algenpantucel-L Immunotherapy | Benzinga  NLNK) - NewLink Genetics Announces Phase 3 Clinical Trial of algenpantucel-L Immunotherapy | Benzinga
NewLink Genetics (NASDAQ: NLNK) announces launching of an open-label, randomized, multi-institutional Phase 3 study in patients with borderline resectable ...
https://www.benzinga.com/news/12/10/2981469/newlink-genetics-announces-phase-3-clinical-trial-of-algenpantucel-l-immunotherap
Prognosis of rectal cancer patients improves with downstaging by intensified neoadjuvant radiochemotherapy - a matched pair...  Prognosis of rectal cancer patients improves with downstaging by intensified neoadjuvant radiochemotherapy - a matched pair...
Neoadjuvant radiochemotherapy has been proven superior to adjuvant treatment in reducing the rate of local recurrence without impairing cancer related survival or the incidence of distant metastases in standard protocols of neoadjuvant radiochemotherapy. The present study aimed at addressing the effects of an intensified neoadjuvant radiochemotherapy on long term cancer related and disease free survival. A total of 387 patients underwent oncologic resection for rectal cancer in our institution between January 2000 and December 2009. There were 106 patients (27.4%) who received an intensified radiochemotherapy protocol completely and without excluding criteria (study group). A matched pair analysis was performed by comparing the study group with patients undergoing primary surgery and postoperative radiochemotherapy, if necessary and possible (control group). Matching was carried out in descending order for UICC stage, R-status, tumor height, T-, N-, V-, L-, M- and G-category of the TNM-system according
https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-13-388/figures/3
Quality of Life With Neoadjuvant Chemoradiotherapy in Esophageal/Esophagogastric Junction Cancer - The ASCO Post  Quality of Life With Neoadjuvant Chemoradiotherapy in Esophageal/Esophagogastric Junction Cancer - The ASCO Post
An analysis in the Dutch Chemoradiotherapy for Esophageal Cancer Followed by Surgery Study (CROSS) reported by Noordman et al in the Journal of Clinical Oncology showed no adverse effect of neoadjuvant chemoradiotherapy vs surgery alone on postsurgery health-related quality of life in patients with esophageal or esophagogastric junction cancer.. Study Details. The CROSS study showed significant improvement in overall survival with neoadjuvant chemoradiotherapy (carboplatin plus paclitaxel with concurrent 41.4-Gy radiotherapy) vs surgery alone. In the current analysis, health-related quality of life was assessed by the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30 (QLQ-C30) and -Oesophageal Cancer Module (QLQ-OES24) questionnaires prior to treatment and at 3, 6, 9, and 12 months after surgery; the neoadjuvant therapy group also received preoperative questionnaires. QLQ-C30 physical functioning and QLQ-OES24 eating problems were predefined primary ...
http://www.ascopost.com/News/58301
Adjuvant chemoradiotherapy may improve survival in head and neck Merkel cell carcinoma  Adjuvant chemoradiotherapy may improve survival in head and neck Merkel cell carcinoma
As a charity, Action Radiotherapy is entirely reliant on donations to support our work. We are extremely grateful to Varian for providing a charitable donation to support our radiotherapy news service. If you would like to receive a daily email with the latest radiotherapy news, please sign up here. ...
http://www.actionradiotherapy.org/adjuvant-chemoradiotherapy-may-improve-survival-in-head-and-neck-merkel-cell-carcinoma/
Assessment of Response Before, During and After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients - Full Text View -...  Assessment of Response Before, During and After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients - Full Text View -...
Rectal cancer is a frequent but curable malignancy in the Western world. The golden standard in treating these patients consists of neoadjuvant chemoradiotherapy (CRT) followed by extensive surgery regardless of tumor response. The main question is whether extensive surgery can be avoided holding in mind that already a significant amount of patients reach a pathological complete response after radiochemotherapy. The goal of this study is dual. First of all, the investigators want to investigate the value of DW-MRI and 18FDG-PET in the assessment of response after neoadjuvant CRT in 100 patients with rectal cancer, to select those patients eligible for less invasive surgery. In the same patient group, the investigators will examine the biomarker potential of molecular characteristics of the tumor in blood and tissue. Using both molecular and radiological findings, the investigators want to predict pathological response after chemoradiotherapy and to select patients who may benefit from treatment ...
https://clinicaltrials.gov/ct2/show/NCT01171300?recr=Open&cond=%22Rectal+Diseases%22&rank=19
Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of...  Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of...
Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of morphological, volumetric and functional MRI parameters Academic Article ...
http://vivo.med.cornell.edu/display/pubid84960112323
Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer | Garvan Institute of...  Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer | Garvan Institute of...
Locally advanced rectal cancer is regularly treated with trimodality therapy consisting of neoadjuvant chemoradiation, surgery and adjuvant chemotherapy. There is a need for biomarkers to assess treatment response, and aid in stratification of patient risk to adapt and personalise components of the therapy. Currently, pathological stage and tumour regression grade are used to assess response. Experimental markers include proteins involved in cell proliferation, apoptosis, angiogenesis, the epithelial to mesenchymal transition and microsatellite instability. As yet, no single marker is sufficiently robust to have clinical utility. Microarrays that screen a tumour for multiple promising candidate markers, gene expression and microRNA profiling will likely have higher yield and it is expected that a combination or panel of markers would prove most useful. Moving forward, utilising serial samples of circulating tumour cells or circulating nucleic acids can potentially allow us to demonstrate tumour
https://www.garvan.org.au/research/publications/13027
Current Concepts on the Distal Margin of Resection of Rectal Cancer Tumors after Neoadjuvant Chemoradiation<...  Current Concepts on the Distal Margin of Resection of Rectal Cancer Tumors after Neoadjuvant Chemoradiation<...
TY - JOUR. T1 - Current Concepts on the Distal Margin of Resection of Rectal Cancer Tumors after Neoadjuvant Chemoradiation. AU - Imran, Jonathan. AU - Yao, Jie J.. AU - Madni, Tarik. AU - Huerta, Sergio. PY - 2017/1/23. Y1 - 2017/1/23. N2 - Purpose of Review: The following review addresses concepts regarding the appropriate distal margin of resection for adenocarcinoma of the rectum in the era of preoperative chemoradiation. Recent Findings: The management of adenocarcinoma of the rectum continues to improve in all aspects of its tri-modality treatment (preoperative chemoradiation, surgery, and adjuvant therapy). The multidisciplinary approach to the management of this disease continues to evolve with a goal to provide better oncologic outcomes with less morbidity in patients affected by this disease. For locoregionally advanced disease, total mesorectal excision continues to be the standard of care for an intended cure for this cohort of patients. As we understand more regarding the oncologic ...
https://utsouthwestern.pure.elsevier.com/en/publications/current-concepts-on-the-distal-margin-of-resection-of-rectal-canc
Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta...  Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta...
We performed a meta-analysis to compare the efficacy of neoadjuvant CRT with OXP plus 5FU to 5FU alone in LARC. The main result of this meta-analysis was that addition of OXP to standard 5FU-based CRT was related to significant clinical benefit in term of DF. Whereas, there was no significant increase in OS, as well as no lower DFS and LF rates were observed between groups, although globally a higher proportion of events was recorded in patients treated with standard CRT.. Nowadays, the treatment of LARC is multidisciplinary and it is developed from clinical trials evidence. The trimodality approach, including neoadjuvant CRT, total mesorectal excision surgery and adjuvant chemotherapy, represents the standard of care in this setting of patients, due to its value to improve local control up to 90% of cases [18]. However it does not decrease distant failures and year after year the concept of intensify treatment regimen has become progressively more common in order to improve systemic control. ...
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3323-4
Assessment of Response Before, During and After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients  Assessment of Response Before, During and After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients
Rectal cancer is a frequent but curable malignancy in the Western world. The golden standard in treating these patients consists of neoadjuvant chemorad
http://www.knowcancer.com/cancer-trials/NCT01171300/
Airway colonisation and postoperative pulmonary complications after neoadjuvant therapy for oesophageal cancer  Airway colonisation and postoperative pulmonary complications after neoadjuvant therapy for oesophageal cancer
Abstract: Objective: To evaluate the clinical relevance of preoperative airway colonisation in patients undergoing oesophagectomy for cancer after a neoadjuvant chemoradiotherapy. Methods: From 1998 to 2005, 117 patients received neoadjuvant chemoradiotherapy for advanced stage oesophageal cancer. Among them, 45 non-randomised patients underwent a bronchoscopic bronchoalveolar lavage (BAL group) prior to surgery to assess airways colonisation. The remaining patients (n =72) constituted the control group. The two groups were similar with respect to various clinical or pathological characteristics. Results: Thirteen of the 45 BAL patients (28%) had a preoperative bronchial colonisation by either potentially pathogenic micro-organisms (PPMs) (n =7, 16%) or non-potentially pathogenic micro-organisms (n =6, 13%). Cytomegalovirus (CMV) was cultured from BAL in four patients. Pre-emptive therapy was administrated in seven patients: four antiviral and three antibiotic prophylaxes. Postoperatively, 14 ...
http://connection.ebscohost.com/c/articles/30018615/airway-colonisation-postoperative-pulmonary-complications-after-neoadjuvant-therapy-oesophageal-cancer
Chair of Proteomics and Bioanalytics: Trimodal mixed mode chromatography enables efficient offline 2D peptide fractionation for...  Chair of Proteomics and Bioanalytics: Trimodal mixed mode chromatography enables efficient offline 2D peptide fractionation for...
Offline two-dimensional chromatography is a common means to achieve deep proteome coverage. To reduce sample complexity and dynamic range and to utilize mass spectrometer (MS) time efficiently, high chromatographic resolution of and good orthogonality between the two dimensions is needed. Ion exchange and high pH reversed phase chromatography are often used for this purpose. However, the former requires desalting to be MS-compatible and the latter requires fraction pooling to create orthogonality. Here, we report an alternative first-dimension separation technique using a commercial trimodal phase incorporating polar embedded reversed phase, weak anion exchange and strong cation exchange material. The column is capable of retaining polar and nonpolar peptides alike without noticeable breakthrough. It allows separating ordinary and TMT-labelled peptides under mild acidic conditions using an acetonitrile gradient. The direct MS compatibility of solvents and good orthogonality to online coupled C18 ...
http://proteomics.wzw.tum.de/index.php?id=11&L=0&tx_ttnews%5Btt_news%5D=61&cHash=94936b5be3a1a6f9ec3c5d105bf1a47b
Chair of Proteomics and Bioanalytics: Trimodal mixed mode chromatography enables efficient offline 2D peptide fractionation for...  Chair of Proteomics and Bioanalytics: Trimodal mixed mode chromatography enables efficient offline 2D peptide fractionation for...
Offline two-dimensional chromatography is a common means to achieve deep proteome coverage. To reduce sample complexity and dynamic range and to utilize mass spectrometer (MS) time efficiently, high chromatographic resolution of and good orthogonality between the two dimensions is needed. Ion exchange and high pH reversed phase chromatography are often used for this purpose. However, the former requires desalting to be MS-compatible and the latter requires fraction pooling to create orthogonality. Here, we report an alternative first-dimension separation technique using a commercial trimodal phase incorporating polar embedded reversed phase, weak anion exchange and strong cation exchange material. The column is capable of retaining polar and nonpolar peptides alike without noticeable breakthrough. It allows separating ordinary and TMT-labelled peptides under mild acidic conditions using an acetonitrile gradient. The direct MS compatibility of solvents and good orthogonality to online coupled C18 ...
http://proteomics.wzw.tum.de/index.php?id=11&tx_ttnews%5Btt_news%5D=61&cHash=94936b5be3a1a6f9ec3c5d105bf1a47b
Phase II Trial of Neoadjuvant Chemoradiation With Bevacizumab for Chinese Locally Advanced Rectal Adenocarcinoma - AdisInsight  Phase II Trial of Neoadjuvant Chemoradiation With Bevacizumab for Chinese Locally Advanced Rectal Adenocarcinoma - AdisInsight
This trial will assess the efficacy and tolerability of neoadjuvant chemoradiotherapy with bevacizumab + oxaliplatin + fluorouracil in patients with locall
http://adisinsight.springer.com/trials/700214945?error=cookies_not_supported&code=98e5067f-6536-4551-b1a2-d8b00ce21896
Exercise During Neoadjuvant CRT Less Difficult Than Anticipated for Rectal Cancer - ONA  Exercise During Neoadjuvant CRT Less Difficult Than Anticipated for Rectal Cancer - ONA
Patients with rectal cancer reported aerobic exercise during neoadjuvant chemoradiotherapy to be more enjoyable and less difficult.
http://www.oncologynurseadvisor.com/navigator-notes/exercise-neoadjuvant-chemotherapy-rectal-cancer-risk-treatment/article/471678/
Increasing the Rates of Complete Response to Neoadjuvant Chemo...  Increasing the Rates of Complete Response to Neoadjuvant Chemo...
Increasing the Rates of Complete Response to Neoadjuvant Chemoradiotherapy for Distal Rectal Cancer: Results of a Prospective Study Using Additional Chemotherap
https://www.mysciencework.com/publication/show/increasing-rates-complete-response-neoadjuvant-chemoradiotherapy-distal-rectal-cancer-results-prospective-study-using-a-cab7e8ef
Clinical correlates of age at onset distribution in bipolar disorder: a comparison between diagnostic subgroups | International...  Clinical correlates of age at onset distribution in bipolar disorder: a comparison between diagnostic subgroups | International...
Admixture analysis of age at onset (AAO) has helped delineating the clinical profile of early onset (EO) bipolar disorder (BD). However, there is scarce evidence comparing the distributional properties of AAO as well as the clinical features of EO BD type 1 (BD1) with EO BD type 2 (BD2). To this end, we studied 515 BD patients (224 BD1, 279 BD2, and 12 BD not otherwise specified [NOS]) diagnosed according to DSM-IV-TR criteria. AAO was defined as the first reliably diagnosed hypo/manic or depressive episode according to diagnostic criteria. We used normal distribution mixture analysis to identify subgroups of patients according to AAO. Models were chosen according to the Schwarzs Bayesian information criteria (BIC). Clinical correlates of EO were analysed using univariate tests and multivariate logistic regression models. A two normal components model best fitted the observed distribution of AAO in BD1 (BIC = −1599.3), BD2 (BIC = −2158.4), and in the whole sample (BIC = −3854.9). A higher number
https://journalbipolardisorders.springeropen.com/articles/10.1186/s40345-017-0097-1
Brevet US4248982 - Clear impact resistant thermoplastic star-block copolymers - Google Brevets  Brevet US4248982 - Clear impact resistant thermoplastic star-block copolymers - Google Brevets
The preparation of a branched, radial block copolymer having improved falling weight impact properties, and having trimodal distribution of molecular structure in the arms of the block copolymer is described.
http://www.google.fr/patents/US4248982
Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer: A meta-analytical evaluation of...  Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer: A meta-analytical evaluation of...
TY - JOUR. T1 - Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer. T2 - A meta-analytical evaluation of prospective studies. AU - Festa, Virginia. AU - Andriulli, Angelo. AU - Valvano, Maria Rosaria. AU - Uomo, Generoso. AU - Perri, Francesco. AU - Andriulli, Nicola. AU - Corrao, Salvatore. AU - Koch, Maurizio. PY - 2013. Y1 - 2013. N2 - Context For patients with borderline resectable pancreatic cancer, the benefit of neoadjuvant therapy remains to be defined. Objective We did a systematic search of the literature on this topic. Methods Prospective studies where chemotherapy with or without radiotherapy was given before surgery to patients with borderline resectable cancer, were analyzed by a metaanalytical approach. Main outcome measures Primary outcome was surgical exploration and resection rates; tumor response, therapy-induced toxicity, and survival were secondary outcomes. Data were expressed as weighted pooled proportions with 95% confidence intervals ...
https://moh-it.pure.elsevier.com/en/publications/neoadjuvant-chemo-radiotherapy-for-patients-with-borderline-resec
Rectal Cancer Response to Preop Chemoradiation Doesnt Rule Out Nodal Disease | Journal Of Clinical Pathways  Rectal Cancer Response to Preop Chemoradiation Doesn't Rule Out Nodal Disease | Journal Of Clinical Pathways
Dr. Rebeccah Baucom of Vanderbilt University in Nashville, Tennessee and colleagues presented the results of the study June 11 at the 2017 American Society of Colon and Rectal Surgeons Annual Scientific Meeting in Seattle, Washington.. "Patients who have rectal cancer with clinical nodal disease, high-grade tumors, or tumors with perineural or lymphovascular invasion should undergo total mesorectal excison regardless of their tumor response to neoadjuvant radiation," said senior author Dr. Alexander T. Hawkins of Vanderbilt University.. "The findings showed that more aggressive tumors, based on histology and stage, do not respond as well to neoadjuvant chemoradiation therapy," he told Reuters Health by phone.. "In a relatively new treatment modality for patients with rectal cancer called watch and wait, patients undergo neoadjuvant chemoradiation therapy, it looks like their tumor goes away, and they can be observed rather than undergo surgery," Dr. Hawkins explained. "Our findings are very ...
http://mtolympusthemepark.com/news/rectal-cancer-response-preop-chemoradiation-doesnt-rule-out-nodal-disease
Plus it  Plus it
Background Patients with locally advanced rectal cancer receive neoadjuvant chemoradiation therapy (CRT) and subsequent surgery. While 10-25% of patients have complete response to CRT, the remaining patients undergo extensive tumor excision resulting in significant quality of life issues. Response to CRT is an independent predictor of overall survival highlighting the importance of improving CRT response rates. Several tumor intrinsic factors govern responses to CRT including specific gene expression programs. Emerging evidence suggests that microRNAs (miRs) modulate gene expression programs in response to radiation and have been implicated in several pathological processes associated with colorectal cancer progression. In this context, we hypothesized that differential expression of miRs regulates colorectal cancer radiation sensitivity and can be used as a biomarker to predict radiation efficacy.. Methods To investigate the differences in miR profiles between rectal cancer patients that had ...
http://cancerres.aacrjournals.org/content/77/13_Supplement/829
Favorable Perioperative Outcomes After Resection of Borderline Resectable Pancreatic Cancer Treated With Neoadjuvant...  Favorable Perioperative Outcomes After Resection of Borderline Resectable Pancreatic Cancer Treated With Neoadjuvant...
Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy in Combination With Bevacizumab-FOLFOX  Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy in Combination With Bevacizumab-FOLFOX
In this phase I trial neoadjuvant CCRT combining IMRT with three escalated dose levels (45 Gy, 50 Gy, and 55 Gy in 25 fractions) and BV-fluorouracil/ le
http://www.knowcancer.com/cancer-trials/NCT01395667/
DataCite Search  DataCite Search
Introduction: Fluorouracil (5-FU) remains the backbone of neoadjuvant radiochemotherapy (RCT) as well as adjuvant therapeutic strategies in multimodal treatment of rectal cancer patients. Due to its central role as the major target of 5-FU thymidylate synthase (TS) is a promising biomarker in rectal[for full text, please go to the a.m. URL ...
https://search.datacite.org/works/10.3205/11DGCH347
Impact of hierarchical pore structure on the catalytic performances of MFI zeolites modified by ZnO for the conversion of...  Impact of hierarchical pore structure on the catalytic performances of MFI zeolites modified by ZnO for the conversion of...
ZnO-containing MFI zeolite catalysts with bimodal and trimodal hierarchical pore structures were prepared, characterized and studied for the conversion of methanol to aromatics. Treatments of H-ZSM-5 with NH4F and NaOH generated bigger micropores with a mean size of around 0.8 nm and mesopores with mean size
http://pubs.rsc.org/en/content/articlelanding/2017/cy/c7cy01041a
Similar Survival With Surgery and Chemoradiotherapy in HPV-Negative Oropharyngeal Squamous Cell Cancer - The ASCO Post  Similar Survival With Surgery and Chemoradiotherapy in HPV-Negative Oropharyngeal Squamous Cell Cancer - The ASCO Post
In an observational study reported in JAMA Oncology, Kelly et al found that overall survival was similar with upfront surgery and definitive chemoradiotherapy among patients with newly diagnosed cT1-2 N1-2b human papillomavirus (HPV)-negative oropharyngeal squamous cell carcinoma.. Study Details. The study involved 1,044 patients from the National Cancer Database who were newly diagnosed between 2010 and 2012. Among them, 460 patients (44.1%) received upfront surgery, and 584 patients (55.9%) received chemoradiotherapy. Median age was 59 years (range, 25-90 years), and 77.8% were male. Adjuvant chemoradiotherapy was received by 59% of surgical patients.. Survival Outcomes. Median follow-up was 30 months. Overall, 3-year overall survival was 81.4% in the surgery group vs 79.2% in the chemoradiotherapy group (P = .65). On multivariable analysis, the adjusted hazard ratio for death for surgery vs chemoradiotherapy was 1.01 (P = .93). In a propensity score-matched cohort of 822 patients, the hazard ...
https://ascopost.com/News/46294
Factors Associated with Local Recurrence After Neoadjuvant Chemoradiation with Total Mesorectal Excision for Rectal Cancer  Factors Associated with Local Recurrence After Neoadjuvant Chemoradiation with Total Mesorectal Excision for Rectal Cancer
The purpose of the present study was to investigate risk factors associated with local recurrence in patients with locally advanced rectal cancer who received preoperative chemoradiotherapy in combination with total mesorectal excision (TME). Rectal cancer patients who were treated with neoadjuvant chemoradiation with TME were studied. We compared 26 patients who developed local recurrence with 119 recurrence-free patients during the follow-up period. The median follow-up period was 52 months (range: 14â€"131 months). Based on the use of univariate and multivariate analyses, circumferential margin involvement ( p = 0.02), the presence of lymphovascular or perineural invasion ( p = 0.02), and positive nodal disease ( p = 0.03) were contributing factors for local recurrence. The local recurrence rate was different between ypN(+) patients and ypN(â€") patients with more than 12 nodes retrieved ( p = 0.01). There was no difference in local recurrence rates between ypN(+) patients and ...
http://connection.ebscohost.com/c/articles/43265283/factors-associated-local-recurrence-after-neoadjuvant-chemoradiation-total-mesorectal-excision-rectal-cancer
Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate...  Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate...
microRNAs (miRNAs) are small non-coding RNAs with important post-transcriptional regulatory functions. miRNA-21 (miR-21) is upregulated and miR-143 and miR-145 are downregulated in colorectal carcinoma. The aim of our study was to determine if these miRNAs change their expression levels in response to neoadjuvant chemoradiotherapy in advanced rectal cancer. Forty patients with advanced rectal cancer (clinical uT3/T4 Nx) were included. All patients underwent neoadjuvant chemoradiotherapy and surgical resection. Expression of miR-21, -143 and -145 was examined in macrodissected tumor tissue before and after chemoradiotherapy and normal rectal tissue from the resection specimen. RNA was extracted from formalin-fixed and paraffin-embedded tissue by TRIzol method, polyadenylated, reverse transcribed and analyzed by real-time PCR. Therapy response was assessed according to pathological tumor regression. miR-21 was more highly expressed in tumor tissue than in non-tumorous tissue. However, there was a ...
https://www.spandidos-publications.com/ijo/39/2/409
Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on...  Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on...
OBJECTIVES: We aimed to examine the association between total number of resected nodes and survival in patients after esophagectomy with and without nCRT. BACKGROUND: Most studies concerning the potentially positive effect of extended lymphadenectomy on survival have been performed in patients who underwent surgery alone. As nCRT is known to frequently "sterilize" regional nodes, it is unclear whether extended lymphadenectomy after nCRT is still useful. METHODS: Patients from the randomized CROSS-trial who completed the entire protocol (ie, surgery alone or chemoradiotherapy + surgery) were included. With Cox regression models, we compared the impact of number of resected nodes as well as resected positive nodes on survival in both groups. RESULTS: One hundred sixty-one patients underwent surgery alone, and 159 patients received multimodality treatment. The median (interquartile range) number of resected nodes was 18 (12-27) and 14 (9-21), with 2 (1-6) and 0 (0-1) resected positive nodes, ...
https://repository.ubn.ru.nl/handle/2066/138947
GastroHep News Story  GastroHep News Story
The researchers identified 6 eligible randomized controlled trials. The team found that chemoradiotherapy plus surgery, compared with surgery alone, significantly reduced the 3 year mortality rate (odds ratio 0.53). They also found that preoperative chemoradiotherapy downstaged the tumor. However, the risk for postoperative mortality was higher in the chemoradiotherapy plus surgery group (odds ratio 2.10). Dr Fiorica and colleagues concluded, In patients with resectable esophageal cancer, chemoradiotherapy plus surgery significantly reduces 3 year mortality compared with surgery alone . However, postoperative mortality was significantly increased by neoadjuvant chemoradiotherapy . Further large scale multicenter randomized controlled trials may prove useful to substantiate the benefit on overall survival . ...
https://www.gastrohep.com/news/news.asp?id=2802
Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of...  Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of...
BACKGROUND We systematically reviewed and performed a meta-analysis of the available data regarding neoadjuvant chemo- and/or radiotherapy with special emphasis on tumor response/progression rates, toxicities, and clinical benefit, i.e. resection probabilities and survival estimates. METHODS AND FINDINGS Trials were identified by searching PUBMED, MEDLINE, and the Cochrane Central Register of Controlled Trials from 1966 to Feb 2015. A total of 18 studies (n = 959) were analyzed. the estimated fraction of patients with complete response was 2.8% (CI 0.8-4.7%) and with partial response 28.7% (CI 18.9%-38.5%). Stable disease was averaged to 45.9% (CI 32.9%-58.9%) in all patients and tumor progression under therapy occurred by estimation in 16.9% (CI 10.2%-23.6%) of the patients. The weighted frequency of those who underwent resection was 65.3% (CI 54.2%-76.5%), and the proportion of R0 resection amounted to 57.4% (CI 48.2%-66.5%). The weighted mean of median survival amounted to 17.9 months (range: 14.7
https://www.semanticscholar.org/paper/Neoadjuvant-therapy-for-patients-with-borderline-r-Tang-Lu/107d83217354a82cba85cb410cc5fa9357c35c9f
Most recent papers in the journal Radiology and Oncology | Read by QxMD  Most recent papers in the journal Radiology and Oncology | Read by QxMD
BACKGROUND: The aim of the study was to evaluate the added value of the apparent diffusion coefficient (ADC) of diffusion-weighted magnetic resonance imaging (DW-MRI) in patients with rectal cancer who received neoadjuvant chemoradiotherapy (CRT). The use of DW-MRI for response evaluation in rectal cancer still remains a widely investigated issue, as the accurate detection of pathologic complete response (pCR) is critical in making therapeutic decisions. PATIENTS AND METHODS: Thirty-three patients with locally advanced rectal cancer were evaluated retrospectively by MRI in addition to diffusion-weighted images (DWI) and its ADC pre- and post-neoadjuvant CRT ...
https://www.readbyqxmd.com/journal/31508
Plus it  Plus it
B71 Background: In locally advanced stages of rectal cancer preoperative combined modality treatment has become the standard therapeutical intervention. Efficacy of neoadjuvant chemoradiation is compromised in some patients by so far unknown factors. These patients could be saved from side effects and surgery could be scheduled without delay. The aim of the present study was to investigate topoisomerase I expression as a potential parameter for predicting tumor response to irinotecan in comparison to adjacent normal tissue.Methods: Twenty patients with rectal cancer clinical stages T3/4 Nx or N+ were recruited to receive weekly neoadjuvant irinotecan (1 hour before radiation) and capecitabine as well as cetuximab with a concurrent RT dose of 50.4 Gy (45+5.4 Gy).Surgery was scheduled 4-6 weeks after the completion of chemoradiation.Samples of normal and tumor tissues of all patients were collected before neoadjuvant treatment. Initially, RNA-oligonucleotid-array of six patients (three ...
http://clincancerres.aacrjournals.org/content/12/19_Supplement/B71
CROSS and beyond: a clinical perspective on the results of the randomized ChemoRadiotherapy for Oesophageal cancer followed by...  CROSS and beyond: a clinical perspective on the results of the randomized ChemoRadiotherapy for Oesophageal cancer followed by...
CROSS and beyond: a clinical perspective on the results of the randomized ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study
http://cco.amegroups.com/article/view/9261/
An Absolute Standardized Uptake Value Is More Useful than the Decreased Rate of Uptake of FDG-PET to Predict Responses to...  An Absolute Standardized Uptake Value Is More Useful than the Decreased Rate of Uptake of FDG-PET to Predict Responses to...
An Absolute Standardized Uptake Value Is More Useful than the Decreased Rate of Uptake of FDG-PET to Predict Responses to Neoadjuvant Chemoradiotherapy for Esophageal Cancer. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
http://libros.duhnnae.com/2017/jun8/149831312178-An-Absolute-Standardized-Uptake-Value-Is-More-Useful-than-the-Decreased-Rate-of-Uptake-of-FDG-PET-to-Predict-Responses-to-Neoadjuvant-Chemoradiotherap.php
Selecting patients for hyperthermia combined with preoperative chemoradiotherapy for locally advanced rectal cancer - Semantic...  Selecting patients for hyperthermia combined with preoperative chemoradiotherapy for locally advanced rectal cancer - Semantic...
This study investigated the role of hyperthermia combined with preoperative concurrent chemoradiotherapy (CCRT) for locally advanced rectal cancer (LARC) according to hypoxic marker expression. One hundred and nine LARC patients with tissue blocks available for immunohistochemical assessment of carbonic anhydrase 9 (CA9) expression were reviewed. CA9 expression was considered positive when the staining percentage of tumor cells was |25% (n = 31). Pelvic radiotherapy with a total dose of 39.6-45 Gy was delivered concurrently with fluorouracil-based chemotherapy. Hyperthermia was administered to 52 patients twice a week during CCRT. Treatment response and outcomes were compared between hyperthermochemoradiotherapy (HCRT) and CCRT groups. In patients with positive CA9 expression, the rates of downstaging (p = 0.060) and pathologic complete response (p = 0.064) tended to be higher in the HCRT group than in the CCRT group. Distant metastasis-free survival (p = 0.029) and cancer-specific survival (p = 0.020)
https://www.semanticscholar.org/paper/Selecting-patients-for-hyperthermia-combined-with-Kim-Yea/12fb38824ef88f8d84aa65f33f53a496a34b62cd
September, 2015 | emailexporter.com  September, 2015 | emailexporter.com
In this review, based mostly on the distribution traits of HLA course I alleles in Chinese populace, we determined putative CD8+ T-mobile epitopes of NS5 protein of Chinese DENV isolates utilizing various immunoinformatics methods. Our benefits provide putative protective CD8+ T-cell epitope candidates or their blend for the advancement of a T-cell epitope-dependent universal vaccine to effectively avoid all four DENV serotypes that are endemic in China.The absolute variety of metastatic lymph nodes has been regarded as as an essential prognostic element for colorectal most cancers. In addition to the quantity of metastatic LNs, the amount of examined LNs has been proven to be an independent prognostic element for survival. Meanwhile, neoadjuvant chemoradiotherapy followed by whole mesorectal excision has become the remedy of option for individuals with LN-constructive rectal cancer. This NCRT can end result in a substantial lessen in the amount and size of examined LNs in the TME specimen. For ...
http://www.emailexporter.com/2015/09/
DI-fusion Review of the quality of total mesorectal excision does not...  DI-fusion Review of the quality of total mesorectal excision does not...
DI-fusion, le Dépôt institutionnel numérique de lULB, est loutil de référencementde la production scientifique de lULB.Linterface de recherche DI-fusion permet de consulter les publications des chercheurs de lULB et les thèses qui y ont été défendues.
http://difusion.ulb.ac.be/vufind/Record/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/236904/Details
Upshot of Therapy for People With Colorectal Cancer Predicted by PET  Upshot of Therapy for People With Colorectal Cancer Predicted by PET
How molecular imaging biomarkers can be applied to estimate howan experimental radiochemotherapy for locally advanced rectal cancer will work revealed by study.
http://www.medindia.net/news/upshot-of-therapy-for-people-with-colorectal-cancer-predicted-by-pet-102715-1.htm
Robotic-assisted total mesorectal excision with the single-docking technique for patients with rectal cancer | BMC Surgery |...  Robotic-assisted total mesorectal excision with the single-docking technique for patients with rectal cancer | BMC Surgery |...
In the past three decades, several advancements including improvement in surgical techniques and the development of new therapeutic modalities have improved treatment outcomes of rectal cancers. Total mesorectal excision (TME) surgery, which was described by Heald and Ryall [1] in 1982, remarkably improves the clinical outcomes of patients with rectal cancer; thus it has served as the standard surgical procedure for such patients. A 5-year local recurrence rate of 5% in patients who undergone TME surgery alone was reported by MacFarlane et al. [2]. In addition, preoperative concurrent chemoradiotherapy (CCRT) considerably helps in improving the local recurrence rate in patients with locally advanced rectal cancer (LARC). A German study reported a considerable decrease in local recurrence in patients receiving preoperative CCRT [3, 4]. The similar results were also reported by other studies [5-7] and preoperative CCRT has been the recommended treatment for patients with LARC.. Laparoscopic rectal ...
https://bmcsurg.biomedcentral.com/articles/10.1186/s12893-017-0315-x
Health-related quality of life of patients treated with primary chemoradiotherapy for oral cavity squamous cell carcinoma: a...  Health-related quality of life of patients treated with primary chemoradiotherapy for oral cavity squamous cell carcinoma: a...
Our aim was to document the health-related quality of life (QoL) of patients with squamous cell carcinoma (SCC) of the oral cavity who were treated with chemoradiotherapy, and to compare it with that of patients treated with conventional surgery with or without adjuvant treatment. All patients who presented with SCC of the oral cavity treated with chemoradiotherapy alone at the Royal Brisbane & Womens Hospital between 2000 and 2011 and who were alive without disease were included. Health-related QoL was assessed by the University of Washington QoL questionnaire version 4, and the European Organisation for the Research and Treatment of Cancer (EORTC) QoL questionnaires C30 and HN35. The questionnaires were sent to all survivors. Those who responded to chemoradiotherapy were matched with patients who were treated by conventional surgery with or without adjuvant treatment by age, sex, subsite of tumour, and TNM stage. Sixteen patients completed the questionnaires (8 in each group). There was no ...
https://espace.library.uq.edu.au/view/UQ:318412
Radiation No Extra Benefit To Stage IIIA/N2 NSCLC Neoadjuvant Chemotherapy | OncologyPRO  Radiation No Extra Benefit To Stage IIIA/N2 NSCLC Neoadjuvant Chemotherapy | OncologyPRO
Neoadjuvant chemoradiotherapy does not offer greater survival for stage IIIA/N2 non-small-cell lung cancer patients than neoadjuvant chemotherapy
http://oncologypro.esmo.org/Topics/Surgery-and-or-Radiotherapy-of-Cancer/Radiation-No-Extra-Benefit-To-Stage-IIIA-N2-NSCLC-Neoadjuvant-Chemotherapy
Plus it  Plus it
Colorectal carcinoma (CRC) is the third most common cancer worldwide with the highest incidence in Central Europe. It is the fourth leading cause of cancer related deaths mainly due to the late diagnosis and low efficacy of treatment. CRC diagnosed in early stage has a five-year survival rate about 90% which drops to near 12% once distant metastases occur. It is a heterogenous disease with different molecular and clinicopathological features depending on the tumor location. Therefore, different treatment strategies are required. A standard treatment of locally advanced rectal cancer includes neoadjuvant chemoradiotherapy followed by surgery, whereas colon cancer treatment consists of surgical resection of the tumor and/or subsequent adjuvant chemotherapy based on disease characteristics. 5-fluorouracil (5-FU) alone or in combination with other compounds is the most used treatment in CRC. The mechanism of 5-FU on molecular level is either its incorporation into DNA or it imbalances the synthesis ...
http://cancerres.aacrjournals.org/content/77/13_Supplement/1424
Localization-specific distributions of protein pI in human proteome are governed by local pH and membrane charge | BMC...  Localization-specific distributions of protein pI in human proteome are governed by local pH and membrane charge | BMC...
Whole-proteome distributions of protein isoelectric point (pI) values in different organisms are bi- or trimodal with some variations. It was suggested that the observed multimodality of the proteome-wide pI distributions is associated with subcellular localization-specific differences in the local pI distributions. However, the factors responsible for variation of the intracellular localization-specific pI profiles have not been investigated in detail. In this work, we explored proteome-wide pI distributions of 32,138 human proteins predicted to reside in 10 subcellular compartments, as well as the pI distributions of experimentally observed lysosomal and Golgi proteins. The distributions were found to differ significantly, although all of them adhered to the major recurrent bimodal pattern. Grossly, acid-biased and alkaline-biased patterns with various minor statistical features were observed at different subcellular locations. Bioinformatics analysis revealed the existence of strong statistically
https://bmcmolcellbiol.biomedcentral.com/articles/10.1186/s12860-019-0221-4
Granule ripples in the Kumtagh Desert, China: Morphology, grain size and influencing factors - QIAN - 2012 - Sedimentology -...  Granule ripples in the Kumtagh Desert, China: Morphology, grain size and influencing factors - QIAN - 2012 - Sedimentology -...
Granule ripples are found mainly in four regions of the Kumtagh Desert in China; they are characterized by an asymmetrical shape, with gentle lower slopes on both sides and abrupt crests. The ripples tend to be oriented perpendicular to the prevailing winds, except when they form near obstacles such as yardangs. The wavelengths (λ) range between 0·31 m and 26 m and heights (h) range from 0·015 m to 1 m. The relationship between wavelength and height can be described by a simple linear function, and the mean ripple index (λ/h) is about 20·4 for the study sites. The sediments are poorly sorted, with negative to very negative skewness at lee and stoss slopes and between-ripple troughs, which confirms the poured in and shadow appearance described by previous researchers. The bimodal or trimodal distributions of grains (with modes of −1·16φ, −0·5φ and 3·16φ) and the enrichment of coarse particles at the ripple surface (with coarse granule contents ranging between 5·2% and 62·1%) ...
http://onlinelibrary.wiley.com/doi/10.1111/j.1365-3091.2012.01330.x/abstract
Rectal Cancer (Clinical)  Rectal Cancer (Clinical)
This course aims to provide in-depth knowledge in the value of MRI during the management of rectal cancer. Attendees will learn how to accurately interpret staging and restaging MR images and deal with difficulties by evaluating numerous cases from daily practice on a personal computer. A faculty of experts in rectal cancer will provide intensive teaching. The goal is that after attending this course the participants will not only be able to implement high quality MR protocol in own center but also to accurately interpret MR images both before and after chemoradiotherapy and to gain own confidence. ...
https://www.esgar.org/workshops/rectal-cancer-clinical/rectal-cancer-amsterdam-2017/
JoVE Author Search: Da Mosto MC  JoVE Author Search: Da Mosto MC
Carcinoma, Patients, Organ Preservation, Surgery, Cell, Chemoradiotherapy, Concurrent Chemoradiotherapy, Platinum, Squamous Cell Carcinoma, Cancer, Eating, Fatigue, Future, Life, Morbidity, Mouth, Organization, Pain, Quality Of Life, Questionnaires
http://labindex.jove.com/author/Da-Mosto-MC
DSpace@MIT: Browsing Chemistry - Ph.D. / Sc.D. by Title  [email protected]: Browsing Chemistry - Ph.D. / Sc.D. by Title
The design, synthesis, and characterization of a series of radicals and biradicals for use as dynamic nuclear polarization (DNP) agents is described. DNP is a method to enhance the S/N-ratio in solid-state nuclear magnetic ...
http://dspace.mit.edu/handle/1721.1/7646/browse?order=ASC&rpp=20&sort_by=1&etal=-1&offset=157&type=title
Rectal adenocarcinoma with oncocytic features: possible relationship to pre-operative chemoradiotherapy | Journal of Clinical...  Rectal adenocarcinoma with oncocytic features: possible relationship to pre-operative chemoradiotherapy | Journal of Clinical...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Centers RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.. ...
http://jcp.bmj.com/content/early/2006/02/07/jcp.2005.031997
RMDRC paleo lab: February 2010  RMDRC paleo lab: February 2010
Pete 3 is rolling along in prep, with 5 jackets finished in the past week (to be fair, 2 of them were 95% done when we shelved the project last May). Im working through the dorsal ribs and gastralia (belly ribs), because theyre quick and easy and usually the last thing anyone wants to work on. The rib head below was finished yesterday, part of the material we had to pull off of the 4-ton jacket early in the prep process. The remainder of the shaft is still on the to-be-prepared shelves, but I hope to get to it very soon. Man, this Daspletosaurus was big ...
http://rmdrc.blogspot.com/2010/02/
Magnetic resonance staging in rectal cancer patients before total mesorectal excision: Efficacy of MR imaging with body coil,...  Magnetic resonance staging in rectal cancer patients before total mesorectal excision: Efficacy of MR imaging with body coil,...
Purpose: To evaluate the efficacy of thin slice and small FOV MRI technique using body coil, performed after distending the rectum with saline solution in the preoperative staging of rectum cancer.. Materials and Methods: MR imaging of 36 patients with rectum cancer was done by distending the rectum with saline solution, using body coil, with thin slices and small FOV parameters. MR staging was done according to the TNM system by consensus of two radiologists using the MR findings of local tumoral invasion, distance to the mesorectal fascia and involvement of local and distant lymph nodes. 12 patients who werent operated were excluded from the study. 24 patients (13 men, 11 women) who underwent operation with total mesorectal excision technique were included in the study. Histopathologic staging of 24 patients were T1,2 and 3 in 2, 10 and 12; and N0,1 and 2 in 13, 7 and 4 patients, respectively. Comparing MR staging results with the histologic staging, sensitivity, specificity, accuracy and ...
https://turkjsurg.com/abstract/30/eng
Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling | Molecular Cancer Research  Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling | Molecular Cancer Research
Preoperative chemoradiotherapy followed by radical surgical resection represents the standard of care for patients with locally advanced rectal cancer (4, 11, 26). However, the response of individual tumors to preoperative multimodal treatment is highly heterogeneous and ranges from complete clinical response to absence of any histopathologic tumor regression (complete resistance). This poses a clinical dilemma, because patients with resistant tumors are exposed to the potential side effects of chemotherapy and irradiation with no clear benefit. It is therefore critical to uncover mechanisms and pathways of treatment resistance for the identification of strategies to increase the fraction of patients with rectal cancer who benefit from multimodal neoadjuvant treatment (10).. In an attempt to identify novel molecular targets and pathways that may be manipulated to sensitize tumors to chemoradiotherapy, we previously demonstrated that the Wnt transcription factor TCF7L2 is overexpressed in ...
https://mcr.aacrjournals.org/content/15/11/1481?ijkey=341cec6a7af5e9e7eaef1757a873d5e2a2d6ba1c&keytype2=tf_ipsecsha
Preoperative chemoradiotherapy versus postoperative chemoradiotherapy for stage II-III resectable rectal cancer: a meta...  Preoperative chemoradiotherapy versus postoperative chemoradiotherapy for stage II-III resectable rectal cancer: a meta...
The initial literature search identified 7,453 studies. We excluded 1,931 duplicates and excluded 5,504 studies by title screening because they did not meet the eligibility criteria. Eighteen randomized controlled trials were selected for full-text review, and 15 papers were discarded; 6 trials compared surgery alone and surgery plus postoperative radiation, 2 compared surgery alone and preoperative longcourse radiation plus surgery, 6 compared surgery alone and preoperative short-course radiation and surgery, and one was long-term results of a previous reported trial. Three randomized trials comparing preoperative CRT with postoperative CRT in resectable stage II-III rectal cancer were finally identified; Park et al. [9] in 2011, Roh et al. [10] in 2009, and Sauer et al. [5] in 2004 (Fig. 1). All patients in both preoperative and postoperative arms received conventionally fractionated radiotherapy of 50-54 Gy with 1.8-2 Gy per fraction for 5-6 weeks. Concurrent chemotherapy of intravenous ...
http://e-roj.org/journal/view.php?number=1330
Treatment strategies for locally advanced rectal cancer with synchronous resectable liver metastasis<...  Treatment strategies for locally advanced rectal cancer with synchronous resectable liver metastasis<...
TY - JOUR. T1 - Treatment strategies for locally advanced rectal cancer with synchronous resectable liver metastasis. AU - Park, Youn Young. AU - Kim, Namkyu. PY - 2018/1/1. Y1 - 2018/1/1. N2 - Approximately one-third of patients with colorectal cancer are estimated to be diagnosed with synchronous liver metastasis (LM). The only method to get cured is to achieve curative resection for both primary and LM. When it comes to locally advanced rectal cancer with synchronous LM, determination of the treatment strategy for each individual is a quite complex procedure, because it demands sophisticated consideration for both local and systemic control. Timing for the application of systemic chemotherapy (CTx), determination of a chemotherapeutic agent, radiation dose and fractions, and sequencing of preoperative treatment and surgeries are all essential components for establishing optimal treatment strategies for the patients with this disease. In this article, treatment strategies proposed in the ...
https://yonsei.pure.elsevier.com/en/publications/treatment-strategies-for-locally-advanced-rectal-cancer-with-sync
Mesothelioma Surgery  Mesothelioma Surgery
Extrapleural pneumonectomy is a very extreme surgery which carries a large chance of severe complications. The procedure requires great skill on the part of the surgeon. Candidates for extrapleural pneumonectomy are carefully selected and must be in good health to survive after the operation. It is usually combined with chemotherapy and radiation as part of trimodal treatment. Recovery typically takes at least a year.. While curative mesothelioma surgeries are not considered to be a cure for mesothelioma, they can extend life by several years and in some cases the cancer is completely eradicated. Unfortunately, most patients are not diagnosed early enough to benefit from curative surgeries.. ...
http://www.mesothelioma.info/mesothelioma-surgery/
Lateral retropharyngeal lymph node metastasis from squamous cell carcinoma of the upper gingiva: A case report  Lateral retropharyngeal lymph node metastasis from squamous cell carcinoma of the upper gingiva: A case report
Lateral retropharyngeal lymph node (LRPLN) is located between the internal carotid artery and the prevertebral muscles. Metastasis to the LRPLN is frequent in nasopharyngeal cancer, but is rare in oral cancer. The prognosis of patients with oral cancer with LRPLN metastasis is usually poor. The present study reported a patient with LRPLN metastasis from squamous cell carcinoma of the upper gingiva, who survived for >7 years. Docetaxel, cisplatin and fluorouracil (TPF) therapy was performed as induction chemotherapy and it was planned to subsequently conduct chemoradiotherapy or surgery. As the tumor only exhibited a transient response to TPF, surgery was selected. Postoperatively, only radiotherapy was performed and a favorable outcome was achieved ...
https://www.spandidos-publications.com/mco/8/1/68
Local Recurrence After Complete Clinical Response and Watch and Wait in Rectal Cancer After Neoadjuvant Chemoradiation: Impact...  Local Recurrence After Complete Clinical Response and Watch and Wait in Rectal Cancer After Neoadjuvant Chemoradiation: Impact...
Purpose: To review the risk of local recurrence and impact of salvage therapy after Watch and Wait for rectal cancer with complete clinical response (cCR) after chemoradiation therapy (CRT). Methods and Materials: Patients with cT2-4N0-2M0 distal rectal cancer treated with CRT (50.4-54 Gy + 5-fluorouracil-based chemotherapy) and cCR at 8 weeks were included. Patients with cCR were enrolled in a strict follow-up program with no immediate surgery (Watch and Wait). Local recurrence-free survival was compared while taking into account Watch and Wait strategy alone and Watch and Wait plus salvage. Results: 90 of 183 patients experienced cCR at initial assessment after CRT (49%). When early tumor regrowths (up to and including the initial 12 months of follow-up) and late recurrences were considered together, 28 patients (31%) experienced local recurrence (median follow-up time, 60 months). Of those, 26 patients underwent salvage therapy, and 2 patients were not amenable to salvage. In 4 patients, ...
https://www.osti.gov/scitech/biblio/22416490-local-recurrence-after-complete-clinical-response-watch-wait-rectal-cancer-after-neoadjuvant-chemoradiation-impact-salvage-therapy-local-disease-control
Risk adjusted benchmarking of clinical anastomotic leakage rate after total mesorectal excision in the context of an...  Risk adjusted benchmarking of clinical anastomotic leakage rate after total mesorectal excision in the context of an...
Sauer Rolf, Fietkau Rainer, Wittekind Christian, Martus Peter, Rödel Claus, Hohenberger Werner, Jatzko Gerhard, Sabitzer Hubert, Karstens Johann-Hinrich, Becker Heinz, Hess Clemens, Raab Rudolf, Adjuvant versus Neoadjuvant Radiochemotherapy for Locally Advanced Rectal Cancer A Progress Report of a Phase-III Randomized Trial (Protocol CAO/ARO/AIO-94) : A Progress Report of a Phase-III Randomized Trial (Protocol CAO/ARO/AIO-94), 10.1007/pl00002396 ...
https://dial.uclouvain.be/pr/boreal/object/boreal:125849
Total mesorectal excision - Wikipedia  Total mesorectal excision - Wikipedia
Total mesorectal excision (TME) is a standard technique for treatment of colorectal cancer, first described in 1982 by Professor Bill Heald at the UKs Basingstoke District Hospital. A significant length of the bowel around the tumour is removed, as is the surrounding tissue up to the plane between the mesorectum and the presacral fascia (Healds "holy plane"). Dissection along this plane facilitates a straightforward dissection and preserves the sacral vessels and hypogastric nerves. It is possible to rejoin the two ends of the colon; however, most patients require a temporary ileostomy pouch to bypass the colon, allowing it to heal with less risk of perforation or leakage.[citation needed] TME has become the "gold standard" treatment for rectal cancer in the West. An occasional side effect of the operation is the formation and tangling of fibrous bands from near the site of the operation with other parts of the bowel. These can lead to bowel infarction if not operated on.[citation needed] TME ...
https://en.wikipedia.org/wiki/Total_mesorectal_excision
6 Committee comments | Transanal total mesorectal excision of the rectum | Guidance | NICE  6 Committee comments | Transanal total mesorectal excision of the rectum | Guidance | NICE
Evidence-based recommendations on transanal total mesorectal excision of the rectum for malignant or benign disease of the rectum (including rectal cancer)
https://www.nice.org.uk/guidance/ipg514/chapter/6-Committee-comments
Phase II Study to Evaluate Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable...  Phase II Study to Evaluate Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable...
Surgical resection is the only potentially curative treatment for patients with pancreatic cancer. Patients with BRPC have tumors in close contact with the vasculature but not to the extent that resection is prohibited. Nonetheless, retrospective studies have shown that immediate resection in these patients is associated with an increased risk of positive margins, and a margin positive resection does not improve survival over that of patients with unresectable disease. Moreover, even in those patients where a successful resection is achieved, there is a high rate of early metastatic progression suggesting that micrometastatic disease is often present at diagnosis. Therefore neoadjuvant therapy is likely to improve outcomes in patients with BRPC to increase the likelihood of achieving a margin negative resection, provide early control of occult micrometastatic disease, and select those patients without systemic progression who would benefit from surgical resection.. ...
http://www.yalestudies.org/categories/1389.trial
A margin distance analysis of the impact of adjuvant chemoradiation on survival after pancreatoduodenectomy for pancreatic...  A margin distance analysis of the impact of adjuvant chemoradiation on survival after pancreatoduodenectomy for pancreatic...
A margin distance analysis of the impact of adjuvant chemoradiation on survival after pancreatoduodenectomy for pancreatic adenocarcinoma
http://jgo.amegroups.com/article/view/13337/html
Introduction to Total Mesorectal Excision - Medical Archives  Introduction to Total Mesorectal Excision - Medical Archives
Colorectal cancer is the second leading cause of mortality in the West, and rectal cancer accounts for about 25% of the colon cancers. The concept of total mesothelial excision (TME) was the most important event in surgery for rectal cancer of the last two decades, because even without a curative approach, it reduced local recurrence and extended 5-year survival. [Med Arch 2017; 71(6.000): 434-438]. Keywords: rectal cancer, TME, mesorectum, CRM, Circumferential Resection Line. >>Full text PDF >>Abstract >>(10.5455/medarh.2017.71.434-438). ...
http://www.medarch.org/2018/01/04/introduction-to-total-mesorectal-excision/
Repeated episodes of spontaneous regression/progression of cervical adenocarcinoma after adjuvant chemoradiation therapy: a...  Repeated episodes of spontaneous regression/progression of cervical adenocarcinoma after adjuvant chemoradiation therapy: a...
Spontaneous regression of cancer is thought to be a rare event. Here, we report an extremely rare case of repeated episodes of spontaneous regression and progression of recurrent cervical adenocarcinoma. We report here a case of a 56-year-old Japanese woman who was diagnosed with cervical adenocarcinoma. Her hilar and mediastinal lymph nodes were swollen 6 years after the initial diagnosis and subsequent treatment, and were found to be pathologically malignant by mediastinal biopsy. Then, without any treatment, the hilar and mediastinal lymph nodes spontaneously regressed with decreases in tumor size and serum tumor marker levels, as confirmed by a decrease in uptake of fluorodeoxyglucose during positron emission tomography-computed tomography. Subsequently, although there were repeated episodes of increase and decrease in her serum tumor marker levels and lymph node size, her activities of daily living were and are well preserved. While spontaneous regression of a malignant tumor is a rare event, our
https://jmedicalcasereports.biomedcentral.com/articles/10.1186/s13256-015-0578-8
Most recent papers with the keyword Watch and wait cancer rectal | Read by QxMD  Most recent papers with the keyword Watch and wait cancer rectal | Read by QxMD
BACKGROUND: Rectum-sparing approaches appear to be appropriate in rectal cancer patients with a major (mCR) or complete clinical response (cCR) after neoadjuvant therapy. The aim of the present study is to evaluate the effectiveness of rectum-sparing approaches at 2 years after the completion of neoadjuvant treatment. STUDY DESIGN: Patients with rectal adenocarcinoma eligible to receive neoadjuvant therapy will be prospectively enrolled. Patients will be restaged 7-8 weeks after the completion of neoadjuvant therapy and those with mCR (defined as absence of mass, small mucosal irregularity no more than 2 cm in diameter at endoscopy and no metastatic nodes at MRI) or cCR will be enrolled in the trial ...
https://www.readbyqxmd.com/keyword/104734
Neoadjuvant therapy for Rectal cancer - ppt video online download  Neoadjuvant therapy for Rectal cancer - ppt video online download
Rectal cancer Improvements in management of rectal cancer in past decades Preoperative accurate tumor staging Good surgical technique (TME) Neoadjuvant / adjuvant therapy Improved pathological assessment identifying adequacy of resection
http://slideplayer.com/slide/1586801/
Advanced Low-Temperature Geothermal Technology  Advanced Low-Temperature Geothermal Technology
Trimodal has developed a revolutionary new highly efficient engine design which is our (LTPC) Engine-expander, which is a positive displacement, compounded, Organic Rankine Cycle expander operating on a binary system. The prime energy sources are non-steam temperature geothermal brines, and industrially sourced waste heat. A major benefit of this technology is that it causes no scaling which is a huge maintenance issues in both geothermal and waste heat recovery. The LTPC system can operate efficiently with temperatures as low as 150F, which is the key to opening low cost, renewable power markets globally. The LTPC engine efficiency obtained is in the area of 55% compared to 25% to 35% efficiency for a turbine using comparable steam. The secondary working fluid is a proprietary organic fluid with a very low boiling point. As an example, 2/3 of the energy of a coal fired power plant goes up the stacks and cooling towers. We can use our engine and their power output can be increased by at least 50% by
http://www.nsti.org/Nanotech2008/showabstract.html?absno=70156
Effect of radiotherapy on sphincter-sparing operations rate in rectal cancer patients | OncologyPRO  Effect of radiotherapy on sphincter-sparing operations rate in rectal cancer patients | OncologyPRO
One hundred and seventy two patients with T2-3N + /-M0 distal rectal cancer had been enrolled. In Group 1 the number of patients was 127, in Group 2 - 45 patients. SSO in Group 1 comprised 43.3% in Group 2 - 91.1% (p> 0.05). A significant increase of SSO rates in women (64.5%) than men (48.9%) was observed (p = 0.04). Age, stage, tumor differentiation, the type of spread didnt affect the SSO rate. ...
http://oncologypro.esmo.org/Topics/Gastrointestinal-Cancers/Rectal-Cancer/Effect-of-radiotherapy-on-sphincter-sparing-operations-rate-in-rectal-cancer-patients
Chemistry Lab: Testing Services - News and Events - NSF International  Chemistry Lab: Testing Services - News and Events - NSF International
The NSF Chemistry Lab performs routine analyses in support of compliance to national and international standards as well as customized testing services and method development. We run over 1 million tests per year, meeting client turnaround times.
http://www.nsf.org/newsroom/news-cat/category/chemistry-lab-testing?date=09-2014
Post-Therapy Pathologic Stage and Survival in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant...  Post-Therapy Pathologic Stage and Survival in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant...
BACKGROUND: Neoadjuvant chemoradiation before surgery is an emerging treatment modality for pancreatic ductal adenocarcinoma (PDAC). However, analysis of prognostic factors is limited for patients with PDAC treated with neoadjuvant chemoradiation and pancreaticoduodenectomy (PD). METHODS: The study population was comprised of 240 consecutive patients with PDAC who received neoadjuvant chemoradiation and PD and was compared with 60 patients who had no neoadjuvant therapy between 1999 and 2007. Clinicopathologic features were correlated with disease-free survival (DFS) and overall survival (OS). RESULTS: Among the 240 treated patients, the 1-year and 3- year DFS rates were 52% and 32%, with a median DFS of 15.1 months. The 1-year and 3-year OS rates were 95% and 47%, with a median OS of 33.5 months. By univariate analysis, DFS was associated with age, post-therapy tumor stage (ypT), lymph node status (ypN), number of positive lymph nodes, and American Joint Committee on Cancer (AJCC) stage, ...
https://laur.lau.edu.lb:8443/xmlui/handle/10725/2646
Curative laparoscopic surgery performed after neoadjuvant chemotherapy for locally advanced rectal cancer invading into the...  Curative laparoscopic surgery performed after neoadjuvant chemotherapy for locally advanced rectal cancer invading into the...
TY - JOUR. T1 - [Curative laparoscopic surgery performed after neoadjuvant chemotherapy for locally advanced rectal cancer invading into the vagina].. AU - Ohtsuka, Masahisa. AU - Mizushima, Tsunekazu. AU - Ohta, Katsuya. AU - Nishimura, Junichi. AU - Takemasa, Ichiro. AU - Ikeda, Masataka. AU - Yamamoto, Hirofumi. AU - Sekimoto, Mitsugu. AU - Doki, Yuichiro. AU - Mori, Masaki. PY - 2011/1/1. Y1 - 2011/1/1. N2 - A 60-year-old woman with locally advanced rectal cancer, which had infiltrated into the vagina, was referred to our department in September 2010. She received 4 courses of neoadjuvant chemotherapy; the tumor size reduced, but the fistula was not closed. Because the tumor size had reduced, we performed a laparoscopic surgery. The laparoscopic surgery involved perineal proctectomy and resection of the posterior wall of the vagina, along with dissection of the bilateral lymph nodes. The efficacy of the neoadjuvant chemotherapy was judged as Grade 2. Neoadjuvant chemotherapy should be ...
https://kyushu-u.pure.elsevier.com/en/publications/curative-laparoscopic-surgery-performed-after-neoadjuvant-chemoth
Effect of leukocyte alteration on treatment outcomes following preoperative chemoradiotherapy in patients with rectal cancer  Effect of leukocyte alteration on treatment outcomes following preoperative chemoradiotherapy in patients with rectal cancer
The radiation dose was a total of 44-45 Gy with 1.8-2 Gy per fraction, using one posterior beam and two bilateral beams with 4-10 megavoltage photons. The radiation field was the whole pelvis, including the primary tumor and the regional lymphatic area with customized portals. In all patients, chemotherapy was delivered concurrently with radiotherapy (RT) consisting of a bolus injection of 5-fluorouracil, 500 mg/m2/day for 3 days per cycle for the first and last week of RT or capecitabine, 850 mg/m2/day twice daily for 5 days per week for 5 weeks. Adjuvant chemotherapy was administered to all but 88 of the patients. All of the subjects underwent curative surgery 6-8 weeks after the end of the CRT, including low anterior resection in 357 patients, abdominopelvic resection in 80 patients, and local excision in 21 patients. After surgery, all tumor specimens were examined by a pathologist, and the post-CRT pathologic stage was evaluated. Well or moderately-differentiated tumors were classified as ...
http://e-roj.org/journal/view.php?number=1335
Adjuvant therapy for T3N0 rectal cancer in the total mesorectal excision era- identification of the high risk patients |...  Adjuvant therapy for T3N0 rectal cancer in the total mesorectal excision era- identification of the high risk patients |...
Adjuvant therapy for T3N0 rectal cancer was controversial with respect to both radiation and the use of a combined regimen of chemotherapy. We evaluated both clinical features and biomarkers and sought to determine risk factors for those patients retrospectively. A total of 122 patients with T3N0 rectal cancer were analyzed in this study from January 2000 to December 2005. Clinicopathologic and biomarkers were used to predict local recurrence (LR), disease-free survival (DFS), and overall survival (OS). The median follow-up interval was 45.4 months. Five-year LR, DFS, and OS rates were 10.4%, 68.3%, and 88.7%. Having a lower tumor location and showing low P21 and high CD44v6 expression were identified as risk factors for LR: patients with two or three of these risk factors had a higher 5-year LR rate (19.3%) than did patients with none or one of these risk factors (6.8%) (p = 0.05). A poorer DFS was related to low P21 nor high CD44v6 expression but not to tumor location: the 5-year DFS rates were 79.3%
https://ro-journal.biomedcentral.com/articles/10.1186/1748-717X-5-118
Efficacy of Once- vs Twice-daily Ratiotherapy for SCLC With Concurrent Chemoradiotherapy  Efficacy of Once- vs Twice-daily Ratiotherapy for SCLC With Concurrent Chemoradiotherapy
Once-daily radiotherapy is not superior to twice-daily treatment for patients with small-cell lung cancer receiving concurrent chemoradiotherapy.
https://www.pulmonologyadvisor.com/lung-cancer/chemoradiotherapy-vs-radiotherapy-for-sclc/article/677890/
Patent US7247482 - Variable resistance sterilization process challenge device and method - Google Patents  Patent US7247482 - Variable resistance sterilization process challenge device and method - Google Patents
A sterilization process challenge device has a sterilization indicator contained within a container; and a variable diffusion restriction into said container.
http://www.google.com.au/patents/US7247482
Safety implications of oesophageal stents used for the palliation of dysphagia in patients undergoing neoadjuvant therapy for...  Safety implications of oesophageal stents used for the palliation of dysphagia in patients undergoing neoadjuvant therapy for...
Safety implications of oesophageal stents used for the palliation of dysphagia in patients undergoing neoadjuvant therapy for oesophageal malignancy
http://jgo.amegroups.com/article/view/2589/3300
Clinical Genomics, MSKCC to Study Rectal Cancer Liquid Biopsy Monitoring | GenomeWeb  Clinical Genomics, MSKCC to Study Rectal Cancer Liquid Biopsy Monitoring | GenomeWeb
Researchers will use the companys Colvera assay to track biomarkers in rectal cancer patients before, during, and after treatment.
https://www.genomeweb.com/molecular-diagnostics/clinical-genomics-mskcc-study-rectal-cancer-liquid-biopsy-monitoring
AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaHumanitiesInformation ScienceHealth CareGeographicals
ChemoradiotherapyChemoradiotherapy, AdjuvantChemotherapy, AdjuvantCombined Modality TherapyRadiotherapy, AdjuvantAdjuvants, ImmunologicFluorouracilEsophageal NeoplasmsNeoadjuvant TherapyCisplatinAntineoplastic Combined Chemotherapy ProtocolsRectal NeoplasmsCarcinoma, Squamous CellRadiotherapy DosageTreatment OutcomeNeoplasm StagingHead and Neck NeoplasmsEsophagectomyDisease-Free SurvivalFreund's AdjuvantRadiotherapySurvival AnalysisSurvival RateAdenocarcinomaNeoplasm Recurrence, LocalDose FractionationNasopharyngeal NeoplasmsDeoxycytidineAntimetabolites, AntineoplasticPrognosisInduction ChemotherapyRetrospective StudiesKaplan-Meier EstimateAntineoplastic AgentsHypopharyngeal NeoplasmsLung NeoplasmsOrgan Sparing TreatmentsDrug Administration ScheduleCarboplatinLaryngeal NeoplasmsFollow-Up StudiesAdjuvants, PharmaceuticDeglutition DisordersRadiation InjuriesPreoperative CareRadiotherapy, ConformalCarcinoma, Non-Small-Cell LungOropharyngeal NeoplasmsPositron-Emission TomographyTaxoidsMucositisPaclitaxelDigestive System Surgical ProceduresLeucovorinLymphatic MetastasisRadiation-Sensitizing AgentsHydroxyureaOrganoplatinum CompoundsBrachytherapyEsophagogastric JunctionRemission InductionFluorodeoxyglucose F18Uterine Cervical NeoplasmsPancreatic NeoplasmsAnus NeoplasmsGastrectomyTegafurOxonic AcidRadiotherapy, Intensity-ModulatedEsophagitisOtorhinolaryngologic NeoplasmsTime FactorsLymph Node ExcisionLaryngectomyFeasibility StudiesPelvic NeoplasmsRandomized Controlled Trials as TopicPostoperative CareCarcinomaLarynxRadiation PneumonitisRadiopharmaceuticalsStomatitisLymphatic IrradiationPneumonectomyStomach NeoplasmsVoice DisordersMitomycinBreast NeoplasmsCyclophosphamideRadiotherapy, High-EnergyEtoposideLeukopeniaTreatment FailureNeoplasm MetastasisNeoplasms, Squamous CellTomography, X-Ray ComputedProspective StudiesAluminum HydroxideClinical Trials, Phase II as TopicClinical Trials as TopicSalvage TherapyProportional Hazards ModelsRadiation DosageMuscle NeoplasmsAntineoplastic Agents, AlkylatingMultivariate AnalysisCarcinoma, Small CellTransplantation, AutologousTumor Markers, BiologicalDose-Response Relationship, RadiationLymph NodesPredictive Value of TestsBone Marrow PurgingBrain NeoplasmsDoxorubicinVinblastinePharyngeal NeoplasmsVincristineRisk AssessmentDisease ProgressionDacarbazineBone Marrow TransplantationNeoplasm InvasivenessCystectomyAntibodies, Monoclonal, HumanizedImmunizationTrismusTamoxifenGlottisNose NeoplasmsMaximum Tolerated DoseIfosfamidePatient SelectionCamptothecinRecurrenceTumor BurdenMultimodal ImagingDrug-Related Side Effects and Adverse ReactionsPostoperative PeriodCarcinoma, Signet Ring CellNeoplasm, ResidualQuality of LifeDrug CombinationsClinical Trials, Phase III as TopicEpirubicinAntineoplastic Agents, HormonalImmunohistochemistryCarcinoma, AdenosquamousMethotrexatePharyngectomyProbabilityDeglutitionRadiation ToleranceVaccinesAdministration, IntranasalNeoplasms, Second PrimaryAmifostineAntibodies, MonoclonalNeck DissectionTracheal NeoplasmsUrinary Bladder NeoplasmsMice, Inbred BALB CJapanMedical OncologyEsophageal FistulaInfusions, IntravenousRisk FactorsRadiation OncologyPostoperative ComplicationsCranial IrradiationGlioblastomaArea Under CurveCohort StudiesSarcomaArthritis, ExperimentalLymphoma, Non-HodgkinNeutropeniaCarcinoma, Large CellAntibody FormationMouth NeoplasmsThoracotomyEndosonographyFatal OutcomeVaccines, SubunitUracilDose-Response Relationship, DrugDilatationMelphalanTriazinesThrombocytopeniaWhole-Body IrradiationImmunoglobulin GSmall Cell Lung CarcinomaPelvic BonesRadiotherapy Planning, Computer-AssistedPreoperative PeriodSqualeneThymidylate SynthaseVaccinationOvalbumin

*Cholangiocarcinoma

Adjuvant therapy followed by liver transplantation may have a role in treatment of certain unresectable cases. If the tumor can ... The role of combined chemoradiotherapy in this setting is unclear. However, if the tumor tissue margins are positive, ... If the tissue margins are negative (i.e. the tumor has been totally excised), adjuvant therapy is of uncertain benefit. Both ... Todoroki T, Ohara K, Kawamoto T, Koike N, Yoshida S, Kashiwagi H, Otsuka M, Fukao K (2000). "Benefits of adjuvant radiotherapy ...

*Cholangiocarcinoma

Adjuvant chemotherapy and radiation therapyEdit. If the tumor can be removed surgically, people may receive adjuvant ... The role of combined chemoradiotherapy in this setting is unclear. However, if the tumor tissue margins are positive, ... Both positive[71][72] and negative[11][73][74] results have been reported with adjuvant radiation therapy in this setting, and ... Adjuvant therapy followed by liver transplantation may have a role in treatment of certain unresectable cases.[70] ...

*Wikipedia:WikiProject Medicine/Cochrane/Cochrane Review List/Musculoskeletal, Oral, Skin and Sensory

De-intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive ... Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small-volume primary oropharyngeal carcinoma PMID 27943254 ... Done Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer PMID 19588382 https://doi. ... Adjuvant antiviral therapy for recurrent respiratory papillomatosis PMID 23235619 https://doi.org/10.1002/14651858.CD005053. ...

*Health care system in Japan

MacDonald (6 September 2001). "Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or ... Sakuramoto (1 November 2007). "Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine". NEJM. 357: 1810-20 ...

*Oliver Cope

Cancer treatment now is focused on limited surgery and adjuvant chemoradiotherapy rather than radical surgery, and medical ...

*Craniopharyngioma

... surgery with adjuvant chemo radiotherapy. The chemotherapy drugs Paclitaxel and Carboplatin have shown a clinical (but not ... There was no link found between malignancy and initial chemo-radiotherapy treatment, and the overall survival rate was very ... Craniopharyngiomas are usually successfully managed with a combination of adjuvant chemotherapy and neurosurgery. Recent ...

*Kurt Hellmann

In the clinical context the orally active Razoxane subsequently was shown to prevent liver metastases in adjuvant treatment of ... More recently it has been demonstrated to potentiate certain schedules of chemoradiotherapy and suppress metastasis in soft ...

*Adjuvant therapy

In glioblastoma multiforme, adjuvant chemoradiotherapy is critical in the case of a completely removed tumor, as with no other ... Adjuvant therapy, also known as adjunct therapy, add-on therapy, and adjuvant care, is therapy that is given in addition to the ... An adjuvant agent modifies the effect of another agent, so adjuvant therapy modifies other therapy. Neoadjuvant therapy, in ... Analgesic adjuvant Chemotherapy, Adjuvant at the US National Library of Medicine Medical Subject Headings (MeSH) Gamal Mostafa ...

*Pancreatic cancer

Clinical trials are often conducted for novel adjuvant therapies. The role of radiotherapy as an auxiliary (adjuvant) treatment ... Before surgery, neoadjuvant chemotherapy or chemoradiotherapy may be used in cases that are considered to be "borderline ... After surgery, adjuvant chemotherapy with gemcitabine or 5-FU can be offered if the person is sufficiently fit, after a ... However, there is a continuing tendency for clinicians in the US to be more ready to use adjuvant radiotherapy than those in ...

*Rak żołądka człowieka, wolna encyklopedia

Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation ... Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. „J Clin Oncol". ... Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. „N Engl J Med". 357 (18), s. 1810-1820, Nov 2007. ... Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised ...

*Colorectal cancer

For locally advanced rectal cancer, neoadjuvant chemoradiotherapy has become the standard treatment.[121] ... radiotherapy can be used in the neoadjuvant and adjuvant setting for some stages of rectal cancer. ... "A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer". International Journal of Biological Sciences ...

*Glioblastoma

Mason, Warren P.; Mirimanoff, René O.; Stupp, Roger (2006). "Radiotherapy with Concurrent and Adjuvant Temozolomide: A New ... "Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas". Journal of Neuro-Oncology. 90 ( ... 2005). "Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma". New England Journal of Medicine. 352 (10): ... Signature and High Epidermal Growth Factor Receptor Expression Associated with Resistance to Concomitant Chemoradiotherapy in ...

*Tecemotide

MPL is also used as adjuvant in other vaccines, e.g. Cervarix which is a vaccine against certain types of cancer-causing human ... versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 ... In this case, Oncothyreon would retain the necessary licenses from GSK required to have the adjuvant MPL manufactured, but the ... Baxter), for the manufacture of tecemotide, and on GlaxoSmithKline plc (GSK) for the manufacture of the adjuvant in tecemotide ...

*Temozolomide

"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a ... "Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas". Journal of Neuro-Oncology. 90 ( ...

*胰臟癌 - 維基百科，自由的百科全書

若病人的情況許可，可在手術後一段時間給予吉西他濱或5-FU等藥物進行輔助性化療（英語：Adjuvant therapy），通常輔助性化療會在術後一至兩個月實施[4][55]。對於身體情況不允許進行治癒性手

*Index of oncology articles

... incomplete Freund's adjuvant - indinavir - indium In 111 ibritumomab tiuxetan - indium In 111 pentetreotide - indole-3-carbinol ... chemoradiotherapy - chemosensitivity - chemosensitivity assay - chemosensitizer - chemotherapeutic agent - chemotherapy - ... adjuvant therapy - adrenocortical - Adriamycin - adult T-cell leukemia/lymphoma - AE-941 - AEE788 - aerobic metabolism - ... immune adjuvant - immune function - immune response - immune system - immune system tolerance - immunoassay - immunocompetence ...

*Health care system in Japan

Sakuramoto (1 November 2007). "Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine". NEJM. 357: 1810-20 ... MacDonald (6 September 2001). "Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or ...
AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaHumanitiesInformation ScienceHealth CareGeographicals
ChemoradiotherapyChemoradiotherapy, AdjuvantChemotherapy, AdjuvantCombined Modality TherapyRadiotherapy, AdjuvantAdjuvants, ImmunologicFluorouracilEsophageal NeoplasmsNeoadjuvant TherapyCisplatinAntineoplastic Combined Chemotherapy ProtocolsRectal NeoplasmsCarcinoma, Squamous CellRadiotherapy DosageTreatment OutcomeNeoplasm StagingHead and Neck NeoplasmsEsophagectomyDisease-Free SurvivalFreund's AdjuvantRadiotherapySurvival AnalysisSurvival RateAdenocarcinomaNeoplasm Recurrence, LocalDose FractionationNasopharyngeal NeoplasmsDeoxycytidineAntimetabolites, AntineoplasticPrognosisInduction ChemotherapyRetrospective StudiesKaplan-Meier EstimateAntineoplastic AgentsHypopharyngeal NeoplasmsLung NeoplasmsOrgan Sparing TreatmentsDrug Administration ScheduleCarboplatinLaryngeal NeoplasmsFollow-Up StudiesAdjuvants, PharmaceuticDeglutition DisordersRadiation InjuriesPreoperative CareRadiotherapy, ConformalCarcinoma, Non-Small-Cell LungOropharyngeal NeoplasmsPositron-Emission TomographyTaxoidsMucositisPaclitaxelDigestive System Surgical ProceduresLeucovorinLymphatic MetastasisRadiation-Sensitizing AgentsHydroxyureaOrganoplatinum CompoundsBrachytherapyEsophagogastric JunctionRemission InductionFluorodeoxyglucose F18Uterine Cervical NeoplasmsPancreatic NeoplasmsAnus NeoplasmsGastrectomyTegafurOxonic AcidRadiotherapy, Intensity-ModulatedEsophagitisOtorhinolaryngologic NeoplasmsTime FactorsLymph Node ExcisionLaryngectomyFeasibility StudiesPelvic NeoplasmsRandomized Controlled Trials as TopicPostoperative CareCarcinomaLarynxRadiation PneumonitisRadiopharmaceuticalsStomatitisLymphatic IrradiationPneumonectomyStomach NeoplasmsVoice DisordersMitomycinBreast NeoplasmsCyclophosphamideRadiotherapy, High-EnergyEtoposideLeukopeniaTreatment FailureNeoplasm MetastasisNeoplasms, Squamous CellTomography, X-Ray ComputedProspective StudiesAluminum HydroxideClinical Trials, Phase II as TopicClinical Trials as TopicSalvage TherapyProportional Hazards ModelsRadiation DosageMuscle NeoplasmsAntineoplastic Agents, AlkylatingMultivariate AnalysisCarcinoma, Small CellTransplantation, AutologousTumor Markers, BiologicalDose-Response Relationship, RadiationLymph NodesPredictive Value of TestsBone Marrow PurgingBrain NeoplasmsDoxorubicinVinblastinePharyngeal NeoplasmsVincristineRisk AssessmentDisease ProgressionDacarbazineBone Marrow TransplantationNeoplasm InvasivenessCystectomyAntibodies, Monoclonal, HumanizedImmunizationTrismusTamoxifenGlottisNose NeoplasmsMaximum Tolerated DoseIfosfamidePatient SelectionCamptothecinRecurrenceTumor BurdenMultimodal ImagingDrug-Related Side Effects and Adverse ReactionsPostoperative PeriodCarcinoma, Signet Ring CellNeoplasm, ResidualQuality of LifeDrug CombinationsClinical Trials, Phase III as TopicEpirubicinAntineoplastic Agents, HormonalImmunohistochemistryCarcinoma, AdenosquamousMethotrexatePharyngectomyProbabilityDeglutitionRadiation ToleranceVaccinesAdministration, IntranasalNeoplasms, Second PrimaryAmifostineAntibodies, MonoclonalNeck DissectionTracheal NeoplasmsUrinary Bladder NeoplasmsMice, Inbred BALB CJapanMedical OncologyEsophageal FistulaInfusions, IntravenousRisk FactorsRadiation OncologyPostoperative ComplicationsCranial IrradiationGlioblastomaArea Under CurveCohort StudiesSarcomaArthritis, ExperimentalLymphoma, Non-HodgkinNeutropeniaCarcinoma, Large CellAntibody FormationMouth NeoplasmsThoracotomyEndosonographyFatal OutcomeVaccines, SubunitUracilDose-Response Relationship, DrugDilatationMelphalanTriazinesThrombocytopeniaWhole-Body IrradiationImmunoglobulin GSmall Cell Lung CarcinomaPelvic BonesRadiotherapy Planning, Computer-AssistedPreoperative PeriodSqualeneThymidylate SynthaseVaccinationOvalbumin
Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma | Scientific ReportsBenefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma | Scientific Reports
... such as chemoradiotherapy (CRT) and chemotherapy (CTx), compared with no adjuvant treatment (No-AT) in resected gallbladder (GB ... adjuvant CRT may improve the LRFS and RFS and subsequently improve OS in lymph node-positive resected GB cancer. ... cancer patients, 151 patients were analyzed: 98 (64.9%) patients received adjuvant treatment with CRT (n = 59, 39.1%) or CTx (n ... Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma. *Tae Hyun Kim. ORCID: orcid.org/0000-0001-8413-33851. ...
more infohttps://www.nature.com/articles/s41598-019-48099-z?error=cookies_not_supported&code=17cbe871-ee5b-460a-936a-c49d50241a76
Efficacy of concurrent chemoradiotherapy plus adjuvant chemotherapy on advanced cervical cancer.Efficacy of concurrent chemoradiotherapy plus adjuvant chemotherapy on advanced cervical cancer.
Concurrent chemoradiotherapy for cervical carcinoma develops rapidly and has become a common and standard therapy in recent ... Chemoradiotherapy* / adverse effects. Chemotherapy, Adjuvant. Cisplatin / adverse effects, therapeutic use. Diarrhea / ... CONCLUSION: Concurrent chemoradiotherapy plus adjuvant chemotherapy for advanced cervical cancer can improve short-term and ... This study aimed to explore the efficacy of concurrent chemoradiotherapy plus adjuvant chemotherapy on and the treatment ...
more infohttp://www.biomedsearch.com/nih/Efficacy-concurrent-chemoradiotherapy-plus-adjuvant/20979696.html
Indirect Comparison Showed Survival Benefit from Adjuvant Chemoradiotherapy in Completely Resected Gastric Cancer with D2...Indirect Comparison Showed Survival Benefit from Adjuvant Chemoradiotherapy in Completely Resected Gastric Cancer with D2...
Three trials compared adjuvant chemoradiotherapy with adjuvant chemotherapy, and 4 trials compared adjuvant chemotherapy with ... Using indirect comparison, the relative hazards of adjuvant chemoradiotherapy to observation were 0.43 (95% CI: 0.33-0.55) in ... and performed indirect comparison to obtain the relative hazards of adjuvant chemoradiotherapy to observation on overall and ... Molecular biomarker might be a promising direction in the prediction of clinical outcome to postoperative chemoradiotherapy, ...
more infohttps://www.hindawi.com/journals/grp/2013/634929/
Neoadjuvant Chemoradiotherapy vs. Chemotherapy With Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer -...Neoadjuvant Chemoradiotherapy vs. Chemotherapy With Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer -...
Radiation: Neoadjuvant Chemoradiotherapy Drug: Neoadjuvant Chemotherapy Procedure: R0 D2 Gastrectomy Drug: Adjuvant ... Neoadjuvant Chemoradiotherapy vs. Chemotherapy With Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer ( ... Drug: Adjuvant Chemotherapy 3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 d1; 21-days/ ... Drug: Adjuvant Chemotherapy 3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 d1; 21-days/ ...
more infohttps://clinicaltrials.gov/ct2/show/NCT01815853
Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by...Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by...
Adjuvant chemotherapy: Q3W for 2 cycles Docetaxel 35 mg/m² IV infusion for 1 hour on D1&8 - Cisplatin 35 mg/m² on D1&8 - ... Response rate (by contrast CT scan) [ Time Frame: 12 weeks after completion of adjuvant chemotherapy or within 4 weeks after ... Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by ... Phase II Study of Concurrent Chemoradiotherapy Using IMRT (With Single Photon Emission Computed Tomography/SPECT-CT to Define ...
more infohttps://clinicaltrials.gov/ct2/show/NCT01266512?cond=%22Lung+Neoplasms%22&lup_s=09%2F16%2F2013&lup_d=30
Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma ...Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma ...
Adjuvant chemoradiotherapy: Within 16-28 days after the first vaccination, patients receive fluorouracil (5-FU) IV continuously ... PURPOSE: This phase II trial is studying how well giving vaccine therapy together with adjuvant chemoradiotherapy works in ... Disease-free Survival in Patients Treated With Adjuvant Chemoradiotherapy in Sequence With the Irradiated Allogeneic GM-CSF ... Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma ...
more infohttps://www.clinicaltrials.gov/ct2/show/study/NCT00084383?term=Pancreatic+Cancer&view=results
Neoadjuvant Chemoradiotherapy May Improve OS Over Adjuvant Standard-of-Care in Pancreatic CancerNeoadjuvant Chemoradiotherapy May Improve OS Over Adjuvant Standard-of-Care in Pancreatic Cancer
... Lisa Astor ... neoadjuvant chemoradiotherapy achieved a median OS of 17.1 months compared with 13.7 months with immediate surgery and adjuvant ... Median DFS was 9.9 months with neoadjuvant chemotherapy and radiation therapy versus 7.9 months with surgery and adjuvant ... Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1 ...
more infohttps://www.onclive.com/conference-coverage/asco-2018/neoadjuvant-chemoradiotherapy-may-improve-os-over-adjuvant-standardofcare-in-pancreatic-cancer
Role of chemoradiotherapy in oesophageal cancer -- adjuvant and neoadjuvant therapy. - Semantic ScholarRole of chemoradiotherapy in oesophageal cancer -- adjuvant and neoadjuvant therapy. - Semantic Scholar
Chemoradiotherapy (CRT), either given before surgical resection as neoadjuvant therapy or after resection as adjuvant therapy, ... Role of chemoradiotherapy in oesophageal cancer -- adjuvant and neoadjuvant therapy.. @article{Gwynne2014RoleOC, title={Role of ... Chemoradiotherapy (CRT), either given before surgical resection as neoadjuvant therapy or after resection as adjuvant therapy, ... Neoadjuvant Chemoradiotherapy Improving Survival Outcomes for Esophageal Carcinoma: An Updated Meta-analysis. *Dong-bin Wang, ...
more infohttps://www.semanticscholar.org/paper/Role-of-chemoradiotherapy-in-oesophageal-cancer-and-Gwynne-Wijnhoven/46f13db97ee15b05782844182d5bee2cdf101be4
RePub, Erasmus University Repository: Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell...RePub, Erasmus University Repository: Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell...
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized ... Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized ... Objective To assess whether afatinib therapy after definitive chemoradiotherapy (CRT) improves disease-free survival (DFS) in ...
more infohttps://repub.eur.nl/pub/119388
Comparative effectiveness of adjuvant chemoradiotherapy after gastrectomy among older patients with gastric adenocarcinoma: a...Comparative effectiveness of adjuvant chemoradiotherapy after gastrectomy among older patients with gastric adenocarcinoma: a...
"Comparative effectiveness of adjuvant chemoradiotherapy after gastrectomy among older patients with gastric adenocarcinoma: a ... received adjuvant CRT. Factors associated with advantage, postoperative chemoradiotherapy (CRT) has adjuvant CRT included age ... received adjuvant CRT. Factors associated with advantage, postoperative chemoradiotherapy (CRT) has adjuvant CRT included age ... Benefit of adjuvant chemoradiotherapy for gastric adenocarcinoma: a SEER population analysis. Seyedin, S; Wang, PC; Zhang, Q; ...
more infohttps://www.deepdyve.com/lp/springer_journal/comparative-effectiveness-of-adjuvant-chemoradiotherapy-after-HXQLbntiDM
Capecitabine as a Radiosensitizer in Adjuvant Chemoradiotherapy for Pancreatic Cancer: A Retrospective StudyCapecitabine as a Radiosensitizer in Adjuvant Chemoradiotherapy for Pancreatic Cancer: A Retrospective Study
... Academic Article ... Concurrent chemoradiation using capecitabine as a radiosensitizer in the adjuvant setting for pancreatic cancer was completed ...
more infohttp://vivo.med.cornell.edu/display/pubid84964695133
Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant...Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant...
Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy (NAC-CCRT) is an alternative strategy for decreasing tumor ... Concurrent chemoradiotherapy followed by adjuvant chemotherapy (CCRT-AC) is currently recommended as the standard treatment for ... Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant ... Concurrent chemoradiotherapy followed by adjuvant chemotherapy (CCRT-AC) is currently recommended as the standard treatment for ...
more infohttps://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4210-3
Postoperative Adjuvant Chemoradiotherapy in Rectal CancerPostoperative Adjuvant Chemoradiotherapy in Rectal Cancer
... Sei Kyung Chang, Jong Woo Kim, Doyeun Oh, So Young Chong, Hyun Soo ... Postoperative Adjuvant Chemoradiotherapy in Rectal Cancer Sei Kyung Chang, Jong Woo Kim, Doyeun Oh, So Young Chong, Hyun Soo ... Postoperative adjuvant chemoradiotherapy was an effective modality for locoregional control of rectal cancer. But further ... To evaluate the role of postoperative adjuvant chemoradiotherapy in rectal cancer, we retrospectively analyzed the treatment ...
more infohttps://www.e-roj.org/journal/view.php?number=353
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of...Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of...
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of ... Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of ... Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of ... Background: The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy versus pelvic ...
more infohttps://discovery.ucl.ac.uk/id/eprint/10079383/
Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy - PubMedPrognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy - PubMed
Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy Eirini Pectasides 1 , ... Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy Eirini Pectasides et al. ... To improve patient selection for adjuvant chemoradiotherapy, we evaluated the prognostic significance of immunohistochemical ... KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced ...
more infohttps://phgkb.cdc.gov/PHGKB/phgHome.action?action=forward&dbsource=phg&id=36898
Adjuvant chemoradiotherapy may improve survival in head and neck Merkel cell carcinomaAdjuvant chemoradiotherapy may improve survival in head and neck Merkel cell carcinoma
... Posted January 21, 2015. by Action ... Postoperative chemoradiotherapy may be associated with improved OS among patients with Merkel cell carcinoma, suggesting the ...
more infohttp://www.actionradiotherapy.org/adjuvant-chemoradiotherapy-may-improve-survival-in-head-and-neck-merkel-cell-carcinoma/
Japanese gastric cancer treatment guidelines 2010 (ver. 3) | SpringerLinkJapanese gastric cancer treatment guidelines 2010 (ver. 3) | SpringerLink
Adjuvant chemotherapy using agents other than S-1. * Neoadjuvant chemoradiotherapy. * Adjuvant chemoradiotherapy ... 6.5 Adjuvant chemotherapy using agents other than S-1. In the West, both postoperative adjuvant chemoradiation [22] and ... 6.7 Adjuvant chemoradiation therapy. Adjuvant chemoradiation therapy has become the standard in the United States since the ... 5 Adjuvant chemotherapy. Adjuvant chemotherapy is delivered with the intention to reduce recurrence by controlling residual ...
more infohttps://link.springer.com/article/10.1007%2Fs10120-011-0042-4
Association of Adjuvant Therapy with Improved Survival in Ampullary Cancer: A National Cohort Study | SpringerLinkAssociation of Adjuvant Therapy with Improved Survival in Ampullary Cancer: A National Cohort Study | SpringerLink
The aim of this study was to determine whether adjuvant therapy was associated with improved survival for... ... Background There are limited data on the efficacy of adjuvant therapy in ampullary cancer. ... 2 Changes in the utilization of adjuvant therapy from 2004 to 2013. ACRT = adjuvant chemoradiotherapy; ACT = adjuvant ... Survival benefit of adjuvant chemoradiotherapy in patients with ampulla of Vater cancer. Ann Surg. 2015;262:47-52.CrossRef ...
more infohttps://link.springer.com/article/10.1007/s11605-017-3624-6
A novel and non-invasive approach utilising nasal washings for the detection of nasopharyngeal carcinoma. - PubMed - NCBIA novel and non-invasive approach utilising nasal washings for the detection of nasopharyngeal carcinoma. - PubMed - NCBI
RT, radiotherapy; NAC, neoadjuvant chemotherapy; AC, adjuvant chemotherapy; CCRT, concurrent chemo‐radiotherapy; CT, ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/30698824
Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer | GutOmega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer | Gut
Adjuvant therapy with traditional chemoradiotherapy. DHA has been shown to potentiate the pro-apoptotic properties of 5- ... Adjuvant treatment with docosahexaenoic acid may improve breast cancer survival and/or reduce cancer-related cachexia. ... both as neoadjuvant/adjuvant treatment in patients undergoing surgery with curative intent and in the management of incurable ...
more infohttps://gut.bmj.com/content/61/1/135
Cancers | Free Full-Text | Immunotherapy, Radiotherapy, and Hyperthermia: A Combined Therapeutic Approach in Pancreatic Cancer...Cancers | Free Full-Text | Immunotherapy, Radiotherapy, and Hyperthermia: A Combined Therapeutic Approach in Pancreatic Cancer...
Chemo radiotherapy. Thermo chemo radiotherapy. Regional hyperthermia. NCT03251365 Phase II and III. Adjuvant chemotherapy ... Post-Surgery, adjuvant Gemcitabine, or 5FU chemo radiation. Post-Surgery, adjuvant Gemcitabine, or 5FU chemo radiation with ... Adjuvant Gemcitabine and Capecitabine. Adjuvant Gemcitabine Cisplatin and regional hyperthermia. Regional hyperthermia. ... Neoadjuvant and adjuvant tumour-targeted RT is often prescribed using a standard fractionation of 1.8-2 Gray (Gy) daily ...
more infohttps://www.mdpi.com/2072-6694/10/12/469/htm
Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma - Full Text View - ClinicalTrials.govDocetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma - Full Text View - ClinicalTrials.gov
Adjuvant chemotherapy. *Adjuvant concurrent or sequential chemoradiotherapy. *Definitive concurrent or sequential ... A patient who is not subject to local treatment such as surgical excision or concurrent definitive chemoradiotherapy. ...
more infohttps://www.clinicaltrials.gov/ct2/show/NCT03585673
Adjuvant chemoradiotherapy after d2-lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. results of a...Adjuvant chemoradiotherapy after d2-lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. results of a...
Adjuvant therapy. Among the 52 individuals treated with adjuvant chemoradiotherapy, 40 completed treatment (76.9%). Regarding ... The role of adjuvant chemoradiotherapy in survival outcomes. In order to identify a specific group of patients who would ... Adjuvant chemoradiotherapy after d2-lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. results of a ... Patients who received adjuvant chemoradiotherapy had 5-year overall survival of 70.9% and disease-free survival of 59.1%. They ...
more infohttp://ro-journal.biomedcentral.com.preview-live.oscarjournals.springer.com/articles/10.1186/1748-717X-7-169
Adjuvant PD-1 Antibody in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma After Chemoradiotherapy: a Multi...Adjuvant PD-1 Antibody in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma After Chemoradiotherapy: a Multi...
This trial is aimed to investigate whether adjuvant PD-1 antibody treatment could improve survival in locoregionally advanced ... Adjuvant PD-1 Antibody in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma After Chemoradiotherapy: a Multi- ... Adjuvant PD-1 Antibody in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma After Chemoradiotherapy: a Multi- ...
more infohttps://adisinsight.springer.com/trials/700292986?error=cookies_not_supported&code=64b1d402-4404-47b4-87ec-04f5f8c4cc21
Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by...Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by...
Tagged as: Adjuvant, Cancer, Carboplatin, Chemoradiotherapy, Chemotherapy, Concurrent, Docetaxelcisplatin, Followed, IMRT, ... Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by ... Previous post: Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin ... Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer ...
more infohttp://lungcancertreatment.org/concurrent-chemoradiotherapy-using-intensity-modulated-radiotherapy-imrt-docetaxel-cisplatin-or-carboplatin-followed-by-adjuvant-chemotherapy-for-inoperable-stage-iii-non-small-cell-lung-can-4048.htm
AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaHumanitiesInformation ScienceHealth CareGeographicals
ChemoradiotherapyChemoradiotherapy, AdjuvantChemotherapy, AdjuvantCombined Modality TherapyRadiotherapy, AdjuvantAdjuvants, ImmunologicFluorouracilEsophageal NeoplasmsNeoadjuvant TherapyCisplatinAntineoplastic Combined Chemotherapy ProtocolsRectal NeoplasmsCarcinoma, Squamous CellRadiotherapy DosageTreatment OutcomeNeoplasm StagingHead and Neck NeoplasmsEsophagectomyDisease-Free SurvivalFreund's AdjuvantRadiotherapySurvival AnalysisSurvival RateAdenocarcinomaNeoplasm Recurrence, LocalDose FractionationNasopharyngeal NeoplasmsDeoxycytidineAntimetabolites, AntineoplasticPrognosisInduction ChemotherapyRetrospective StudiesKaplan-Meier EstimateAntineoplastic AgentsHypopharyngeal NeoplasmsLung NeoplasmsOrgan Sparing TreatmentsDrug Administration ScheduleCarboplatinLaryngeal NeoplasmsFollow-Up StudiesAdjuvants, PharmaceuticDeglutition DisordersRadiation InjuriesPreoperative CareRadiotherapy, ConformalCarcinoma, Non-Small-Cell LungOropharyngeal NeoplasmsPositron-Emission TomographyTaxoidsMucositisPaclitaxelDigestive System Surgical ProceduresLeucovorinLymphatic MetastasisRadiation-Sensitizing AgentsHydroxyureaOrganoplatinum CompoundsBrachytherapyEsophagogastric JunctionRemission InductionFluorodeoxyglucose F18Uterine Cervical NeoplasmsPancreatic NeoplasmsAnus NeoplasmsGastrectomyTegafurOxonic AcidRadiotherapy, Intensity-ModulatedEsophagitisOtorhinolaryngologic NeoplasmsTime FactorsLymph Node ExcisionLaryngectomyFeasibility StudiesPelvic NeoplasmsRandomized Controlled Trials as TopicPostoperative CareCarcinomaLarynxRadiation PneumonitisRadiopharmaceuticalsStomatitisLymphatic IrradiationPneumonectomyStomach NeoplasmsVoice DisordersMitomycinBreast NeoplasmsCyclophosphamideRadiotherapy, High-EnergyEtoposideLeukopeniaTreatment FailureNeoplasm MetastasisNeoplasms, Squamous CellTomography, X-Ray ComputedProspective StudiesAluminum HydroxideClinical Trials, Phase II as TopicClinical Trials as TopicSalvage TherapyProportional Hazards ModelsRadiation DosageMuscle NeoplasmsAntineoplastic Agents, AlkylatingMultivariate AnalysisCarcinoma, Small CellTransplantation, AutologousTumor Markers, BiologicalDose-Response Relationship, RadiationLymph NodesPredictive Value of TestsBone Marrow PurgingBrain NeoplasmsDoxorubicinVinblastinePharyngeal NeoplasmsVincristineRisk AssessmentDisease ProgressionDacarbazineBone Marrow TransplantationNeoplasm InvasivenessCystectomyAntibodies, Monoclonal, HumanizedImmunizationTrismusTamoxifenGlottisNose NeoplasmsMaximum Tolerated DoseIfosfamidePatient SelectionCamptothecinRecurrenceTumor BurdenMultimodal ImagingDrug-Related Side Effects and Adverse ReactionsPostoperative PeriodCarcinoma, Signet Ring CellNeoplasm, ResidualQuality of LifeDrug CombinationsClinical Trials, Phase III as TopicEpirubicinAntineoplastic Agents, HormonalImmunohistochemistryCarcinoma, AdenosquamousMethotrexatePharyngectomyProbabilityDeglutitionRadiation ToleranceVaccinesAdministration, IntranasalNeoplasms, Second PrimaryAmifostineAntibodies, MonoclonalNeck DissectionTracheal NeoplasmsUrinary Bladder NeoplasmsMice, Inbred BALB CJapanMedical OncologyEsophageal FistulaInfusions, IntravenousRisk FactorsRadiation OncologyPostoperative ComplicationsCranial IrradiationGlioblastomaArea Under CurveCohort StudiesSarcomaArthritis, ExperimentalLymphoma, Non-HodgkinNeutropeniaCarcinoma, Large CellAntibody FormationMouth NeoplasmsThoracotomyEndosonographyFatal OutcomeVaccines, SubunitUracilDose-Response Relationship, DrugDilatationMelphalanTriazinesThrombocytopeniaWhole-Body IrradiationImmunoglobulin GSmall Cell Lung CarcinomaPelvic BonesRadiotherapy Planning, Computer-AssistedPreoperative PeriodSqualeneThymidylate SynthaseVaccinationOvalbumin
Combined adjuvant chemotherapy and radPreoperative chemoradiotherapyFollowed by Adjuvant ChemotherapyDefinitive chemoradiotherapyCisplatinRectal cancerRelapse-free survivalReceive adjuvantLocally advancedSurgicalPhase III trial of adjuvantSurgery and adjuvant chemotherapyOutcomesGastrectomy and adjuvantCompared adjuvant chemotherapyConcomitantGemcitabineReceived adjuvant treatmentFluorouracilPancreaticModality TherapyDisease-free survivalTherapeuticEsophagealBenefitClinicalRadiation therapyRetrospective studySquamous

Combined adjuvant chemotherapy and rad1

search

Preoperative chemoradiotherapy8

search

Followed by Adjuvant Chemotherapy1

search

Definitive chemoradiotherapy9

search

Cisplatin3

search

Rectal cancer13

search

Relapse-free survival4

search

Receive adjuvant2

search

Locally advanced2

search
  • Because chemoradiotherapy with FP is an important component in the management of both resectable and unresectable locally advanced esophageal cancer, the determination of parameters that may identify those patients who would benefit from chemoradiotherapy and who would not has strong clinical implications. (aacrjournals.org)
  • Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ≥70years. (usf.edu)

Surgical9

search

Phase III trial of adjuvant2

search

Surgery and adjuvant chemotherapy1

search

Outcomes2

search

Gastrectomy and adjuvant2

search

Compared adjuvant chemotherapy1

search

Concomitant2

search

Gemcitabine1

search

Received adjuvant treatment1

search

Fluorouracil4

search

Pancreatic5

search

Modality Therapy1

search

Disease-free survival2

search
  • We conducted a systematic review of randomized controlled trials, extracted time-to-event data using Tierney methods (when not reported), and performed indirect comparison to obtain the relative hazards of adjuvant chemoradiotherapy to observation on overall and disease-free survival. (hindawi.com)
  • The purpose of this study is to determine whether 6 years adjuvant anastrozole will improve the disease free survival compared to 3 years adjuvant anastrozole in postmenopausal hormone sen. (bioportfolio.com)

Therapeutic1

search
  • Because of the low incidence of GB cancer, prospective clinical studies to investigate the role and compare the effectiveness of different adjuvant therapeutic modalities, such as CRT and CTx, for GB cancer are difficult to conduct and have rarely been performed. (nature.com)

Esophageal1

search

Benefit8

search

Clinical1

search

Radiation therapy2

search

Retrospective study2

search

Squamous1

search